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ABSTRACT 
 
 
Punta Toro Virus Infection in Mice:  Strain Differences in Pathogenesis and Regulation 
of Interferon Response Pathways  
 
 
by 
 
Michelle Mendenhall, Master of Science 
Utah State University, 2009 
 
Major Professor: Brian B. Gowen 
Department: Animal, Dairy and Veterinary Science 
 
 The Adames strain of Punta Toro virus (PTV-A) causes acute hepatic disease in 
hamsters and mice similar to that seen in natural Rift Valley fever virus (RVFV) 
infection, while the Balliet strain (PTV-B) is apathogenic.  The ability of PTV-A to 
suppress the interferon (IFN) response has been demonstrated in hamsters and is thought 
to be a contributing factor to PTV-A’s pathogenicity in hamsters.  PTV-B is not assumed 
to exhibit this IFN-antagonistic activity, as it stimulates production of significantly higher 
IFN-β levels.  To elucidate the role of IFN in resistance of mice to PTV-B infection, we 
utilized mice deficient in a critical IFN signaling protein, STAT-1.  We found that these 
mice were drastically more susceptible to PTV-B, which caused 100% lethality compared 
to 0% in their wild-type counterparts.  STAT-1 deficient mice were also more susceptible 
to PTV-A, as these mice succumbed to infection significantly earlier than wildtype mice 
(p=0.0058).  We sought to determine whether PTV-A’s IFN-antagonistic mechanism is 
 iii
functional in mice by examining expression of IFN-β in primary macrophages infected 
with either strain.  We found that IFN-β protein concentration is higher in samples taken 
from PTV-B-infected cells.  We employed quantitative PCR arrays specific to IFN 
signaling and response pathways to evaluate changes in gene expression throughout the 
course of infection with either virus strain.  We found several genes with differentially 
regulated expression between PTV-A- and PTV-B-infected macrophages, including Ifnβ1 
and multiple Ifnα subtypes.  Also, several genes coding for inflammatory and 
chemotactic molecules, Cxcl11, Cxcl10, Cxcl9, Vcam1, and Il6, demonstrated increased 
expression in PTV-B samples compared to PTV-A.  Of particular interest, Isg20, a 3’-5’ 
exonuclease with specificity for single-stranded RNA, was stimulated ~2-fold higher by 
PTV-B, and Iigp1, from the family of GTPases associated with host defense against 
intracellular pathogens, was stimulated ~2.7-fold higher by PTV-B.  The individual 
functions of each of these genes in mouse resistance to PTV-B could be a focus of future 
studies to better understand essential host defense mechanisms to phleboviral infection. 
 
(92 pages) 
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CHAPTER 1 
 
INTRODUCTION 
 
Rift valley fever (RVF) is an acute, febrile disease of domestic ruminants, 
especially sheep, cattle and goats, which can also be transmitted to humans.  The disease 
had caused extensive losses of sheep and cattle in Kenya before the turn of the century, as 
well as a liver disease in humans during certain wet years (Shimshony and Barzilai, 1983; 
Swanepoel and Coetzer, 1994), but the causative agent was not discovered until 1930, 
when Daubney et al. (1931) isolated the virus in the Rift Valley area of Kenya and 
demonstrated its destructive action on hepatic cells.  Studies after 1931 revealed the wide 
host range of the virus, including domestic, wild and laboratory animals (Shimshony and 
Barzilai, 1983).  Rift Valley fever virus has since been the agent of multiple outbreaks 
outside of the sub-Saharan region (Abdo-Salem et al., 2006; CDC, 2000a, 2000b; 
Meegan et al., 1979).   The capacity of RVFV to cause disease and economic tumult in 
various geographical areas, along with its ease of transmission and lack of effective 
treatments has resulted in its classification as a category A pathogen by the National 
Institute of Allergy and Infectious Disease (NIAID) (Sidwell et al., 1992; Sidwell and 
Smee, 2003).    
Due to stringent enhanced biosafety level 3 (BSL-3) requirements for working 
with RVFV, Punta Toro virus (PTV), a closely related phlebovirus, has been employed as 
a model virus for inducing acute phleboviral disease (Anderson et al., 1990; Fisher et al., 
2003; Pifat and Smith, 1987).  The Adames strain of PTV (PTV-A) induces disease in 
hamsters and weanling mice similar to that seen in natural RVFV infections, and 
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therefore serves as a safer and more cost effective alternative to study disease.  In our 
lab we have found PTV-A to effectively induce disease in adult mice (Gowen and 
Holbrook, 2008; Gowen et al., 2006b) but disease pathology and characteristics have yet 
to be established in this model.   
A second strain of PTV, Balliet (PTV-B), is found to be of low pathogenicity in 
hamsters, which survive infection even at very high virus doses (Anderson et al., 1990).  
Perrone and coworkers (2007) recently discovered an interferon (IFN)-antagonistic 
function utilized by PTV-A, but not PTV-B, which helps explain the greater success of 
the Adames strain in establishing infection in hamsters.  This discovery is important in 
that it establishes a connection between PTV-A and RVFV, as both encode a non-
structural protein, NSs, that exhibit similar IFN-antagonistic activity.  Preliminary studies 
in our lab illustrate that PTV-B is also apathogenic in adult mice, though it is not known 
whether the IFN-antagonistic activity demonstrated by PTV-A in a hamster-derived 
system is effective in mice.  In viral infections, the IFN signaling pathway can regulate 
transcription of hundreds of factors that interact to induce an antiviral state.  The first 
type I IFN produced is IFN-β, which initiates a burst of multiple IFN-α subtypes (Marie 
et al., 1998).  The type I IFNs bring about transcription of many genes coding for proteins 
with various antiviral activities.  PTV-A is effective in suppressing the IFN-β promoter 
(Perrone et al., 2007), therefore interrupting the signaling chain of events at the outset, 
and arresting a great deal of the IFN pathway and its effectors.  Although IFN-β is the 
central molecule to the workings of the IFN pathway, the regulation of downstream 
effector molecules has not been explored in relation to phleboviral infection.  Though it 
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seems likely that a multitude of genes controlled by IFN signaling would be suppressed, 
there is no evidence that this is the case. 
The first objective of my research was to examine the disease pathology of PTV-
A and PTV-B infections in adult mice to better characterize the model for phleboviral-
induced disease.  We ascertained that PTV-B does not cause disease in mice, and I 
conducted studies to determine whether this resistance is due to a more effective IFN 
response to the virus.  Mice deficient in STAT-1, a crucial protein in the IFN signaling 
cascade, were employed to address this question.  Finally, I examined the regulation of 
IFN signaling and response genes following exposure to infection with PTV-A and PTV-
B.  These studies were conducted in primary mouse macrophages, as these IFN-
competent cells are a major target of PTV and play a critical role in antiviral innate 
immunity through the induction of type I IFNs and other inflammatory mediators.  
 
LITERATURE REVIEW 
 
Rift Valley Fever 
 Major outbreaks of RVF in Kenya occurred in 1930-31, 1968, and 1978-79.  The 
disease was first recorded in southern Africa in late 1950, during a huge epidemic in 
which 100,000 sheep died and 500,000 aborted, and also included less significant cattle 
losses.  Less severe outbreaks in South Africa were recorded in 1952-53, 1955-59, 1969-
71, and 1981.  The first human deaths were reported in a major epidemic in South Africa 
in 1975, when several patients died of encephalitis and hemorrhagic fever associated with 
necrotic hepatitis (Swanepoel and Coetzer, 1994).   Before 1977, Sudan was the furthest 
north that disease had been reported, but in October of that year, Egypt was plagued with 
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a major outbreak (Meegan et al., 1979), which, aside from widespread abortions and 
mortality in sheep and cattle, also resulted in an estimated 200,000 human cases and >600 
deaths (Sidwell and Smee, 2003).  This was the disease’s first extension beyond the sub-
Saharan range. 
 To date, RVFV has spread >7000 km north-south throughout Africa, in a variety 
of climates and geographical settings (Shimshony and Barzilai, 1983).  Its success in 
Egypt illustrated its ability to spread past its previous geographical restriction of sub-
Saharan Africa.  In its first extension outside of Africa, RVFV has been responsible for 
recent outbreaks in Saudi Arabia and Yemen (Abdo-Salem et al., 2006; CDC, 2000b, 
2000c), further demonstrating its ability to survive in various regions where its host 
reservoirs and vector are abundant.  Taken together, the relative ease of propagating 
RVFV, its ability to induce serious illness for which there are no approved therapies, and 
its transmissibility by aerosol exposure underscore the potential bioterror threat.  To this 
end, the NIAID has classified RVFV as a category A pathogen (NIAID, 2002).  In the 
case of intentional release of RVFV, high mortality among humans and domesticated 
livestock is probable, along with the possibility of disease establishment and persistence 
in the environment. 
It has been shown that the RVFV can be maintained between outbreaks in nature 
via transovarial transmission in mosquitoes (Linthicum et al., 1985; Nichol, 2001; Zeller 
and Bouloy, 2000), and it is thought that RVFV is dependant on this mechanism for 
survival during inter-epizootics (Bouloy et al., 2001; Nichol, 2001).  Heavy rainfall 
leading to flooding promotes the hatching of virus-bearing mosquito eggs, and these 
mosquitoes feed on livestock that can act as an amplifying host (Nichol, 2001).  
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However, more evidence is necessary to confirm this concept.  Vertebrates that have 
demonstrated potential to act as the reservoir include the Namaqua rock rat (Aethomys 
namaquensis) in South Africa (Pretorius et al., 1997), and bats (Oelofsen and Van der 
Ryst, 1999). 
 Aedes species of mosquitoes are believed to be the principal vectors for RVFV 
(Linthicum et al., 1985; Nichol, 2001).  Transmission in livestock generally occurs 
through mosquito feeding.  Likewise, humans can be infected through mosquito bites, but 
contact transmission appears to be the major route of transmission, and it is often those 
that work with or process livestock that acquire the illness.  RVFV is also infectious in 
aerosol form, which has led to infection of laboratory employees working with the virus 
(Nichol, 2001). 
 
Clinical signs and pathology  
RVFV belongs to the group viral hemorrhagic fever (VHF) agents.  This group 
comprises single-stranded RNA viruses from four different virus families, Bunyaviridae, 
Arenaviridae, Filoviridae, and Flaviviridae, which cause illness characterized by fever 
and malaise, along with increased vascular permeability and coagulation defects leading 
to a fall in plasma volume and hemorrhaging (Bray, 2005; Geisbert and Jahrling, 2004).  
VHF viruses are able to replicate successfully in macrophages, likely impairing function 
and stimulating the release of cytokines, chemokines and other mediators, leading to 
changes in vascular permeability and procoagulatory state (Bray, 2005).  Further, 
suppression of the host type I IFN response by some VHF agents facilitates rapid 
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dissemination.  In combination, these features promote systemic changes, which are 
often detrimental to the host.   
 Clinical signs of RVF are generally non-specific, making it difficult to identify 
individual cases of the disease.  In severe cases, the clinical disease may be acute with a 
rapid febrile reaction and death within 24-48 hours.  Clinical signs in sheep and goats are 
anorexia, vomiting, rapid pulse, increased respiration rate, nasal discharge, disinclination 
to move, unsteady gait, lameness, hemorrhagic diarrhea, and abortion in pregnant cows 
and ewes (Shimshony and Barzilai, 1983; Swanepoel and Coetzer, 1994).  In subacute 
cases of the disease, fever lasts 24-96 hours, with less severe signs of anorexia and 
weakness.  Infection is often unapparent in adult cattle, but many develop signs similar to 
that of sheep, as well as increased salivation and dry skin.   The most telling sign of a 
RVF epidemic is sudden “abortion storms” in livestock, in which 40-100% of pregnant 
ewes and cows abort.  Mortality generally ranges from 20-30% in adult sheep and about 
10% in cattle, while young animals 1-2 weeks of age can experience >90% mortality 
(Swanepoel and Coetzer, 1994).  In a RVF epidemic, economic losses can be devastating. 
In humans, RVF symptomology is often reminiscent of influenza, with a sudden 
onset of chills, headache, backache, myalgia, diarrhea, vomiting and fever.  Though 
infection rarely causes serious illness, severe cases may lead to late-onset encephalitis or 
a hemorrhagic state that usually results in death (Nichol, 2001; Sidwell and Smee, 2003; 
Swanepoel and Coetzer, 1994).  Mortality rates are usually ~1% in humans, although 
some outbreaks have had significantly higher rates.   
 In cases of hemorrhagic syndrome, it is though that disseminated intravascular 
coagulopathy (DIC), a systemic activation of coagulation pathways, plays a major role in 
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disease pathogenesis, as it does in other VHF diseases (Bray, 2005; Geisbert and 
Jahrling, 2004; Swanepoel and Coetzer, 1994).  Hemostatic studies performed in 
monkeys illustrate prolonged activated partial thromboplastin and prothrombin times.  
Depletion of coagulation factors II, V, VII, IX, X, XII, and fibrinogen, as well as 
thrombocytopenia, platelet dysfunction, and increased fibrin degradation product levels 
suggest that DIC may be a key factor in disease pathogenesis (Cosgriff et al., 1989; 
Morrill et al., 1990; Swanepoel and Coetzer, 1994).  The presence of fibrin thrombi in the 
liver, spleen, kidney, and lungs of sheep and cattle indicate that DIC is also a feature of 
RVF in domestic ruminants (Swanepoel and Coetzer, 1994). 
 Retinal vasculitis or encephalitis can be observed in humans 1 to 4 weeks after 
acute illness and encephalitic cases can progress to coma and death.  There is no evidence 
of true viral encephalitis in that the virus is not known to replicate in neurological tissue 
and it is suspected that an immunopathological component may play a role in this late-
onset of the disease (Nichol, 2001).   
 The antibody response to RVFV may be delayed and weak, but can usually be 
detected 2-4 days after infection using methods such as neutralization, hemagglutination 
inhibition, and complement fixation (Shimshony and Barzilai, 1983).  Viremia is 
observed from 1-7 days after infection.  Leukopenia occurs in the first 3-4 days, usually 
corresponding with peak fever and viremia (Swanepoel and Coetzer, 1994).  Marked 
increases in serum enzymes such as alanine aminotransferase, gamma-
glutamyltransferase, aspartate aminotransferase, sorbitol dehydrogenase, glutamate 
dehydrogenase, and lactate dehydrogenase indicate hepatocyte necrosis/degeneration and 
liver dysfunction (Cosgriff et al., 1989; Morrill et al., 1990; Rippy et al., 1992; 
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Swanepoel and Coetzer, 1994).  In human hemorrhagic cases slightly elevated bilirubin, 
decreased prothrombin, increased alanine and aspartate aminotransferases and urea levels 
are observed indicating both hemolysis and liver damage (Shimshony and Barzilai, 
1983). 
 
RVF produces severe hepatitis and 
widespread hemorrhaging  
 
The major organ affected during RVFV infection is the liver (Fisher et al., 2003; 
Swanepoel and Coetzer, 1994) though hemorrhaging is observed in multiple other 
systems.  Gross lesions associated with RVF are similar in sheep and cattle but may vary 
depending on the age of the animal.  In young lambs the liver is enlarged, soft, friable, 
and yellowish-brown to dark red.  Numerous gray to white necrotic foci, 1-2 mm in 
diameter, are scattered throughout the parenchyma, along with petechiae and focal 
congestion.  The gall bladder may be edematous with hemorrhaging.  The liver is 
similarly affected in adult sheep and cattle, demonstrating hemorrhages and necrotic foci, 
but to a lesser extent (Coetzer, 1982; Shimshony and Barzilai, 1983).  In humans, a 
similar pattern is also observed, where the liver is enlarged and yellowish brown with 
petechiae and necrotic areas obscuring the lobular pattern. 
As expected, changes in the liver are also the most obvious microscopic change, 
where there are multifocal to coalescing areas of centrilobular hepatic necrosis.  Dense 
aggregates of cytoplasmic and nuclear debris, fibrin, acidophilic bodies, neutrophils, and 
macrophages are seen in necrotic areas.  These areas have pyknosis, karyorrhexis and 
cytolysis and destruction of hepatocytes may be so intense that most of the normal organ 
architecture is lost (Rippy et al., 1992; Shimshony and Barzilai, 1983; Swanepoel and 
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Coetzer, 1994).  Icterus is also common in older sheep though not in young lambs. 
RVFV-infected cattle have a similar histological picture, but vasculitis, thrombosis and 
sinusoidal fibrin deposition in the liver may also be seen.  Humans also demonstrate 
comparable manifestations to those seen in domestic livestock, with widespread 
congestion and necrotic areas (Shimshony and Barzilai, 1983).  
Hemorrhaging has been observed in multiple other organ systems, including the 
spleen, lungs, kidneys, adrenal gland, pericardium, gastrointestinal tract, and peripheral 
and visceral lymph nodes (Daubney et al., 1931; Shimshony and Barzilai, 1983; 
Swanepoel and Coetzer, 1994).  The spleen is slightly enlarged with hemorrhages in 
capsule and may have evidence of infarcts on the edges both grossly and microscopically.  
In cattle, there may also be necrosis of lymphoid tissue and numerous foci containing 
fibrin in the red pulp of the spleen (Swanepoel and Coetzer, 1994). Tubular and 
glomerular degeneration, and proteinaceous droplets are often present in the kidneys and 
emphysema and congestion can be seen in the lungs.  Although late-onset encephalitis 
may occur from one to four weeks after infection, significant pathological changes have 
not been described in the nervous system of livestock or humans (Daubney et al., 1931; 
Swanepoel and Coetzer, 1994).  
 
The virus genome and IFN-antagonistic  
activity 
 RVFV is a member of the phlebotomus fever group of the Bunyaviridae family of 
viruses.  The virus is spherical, 80-120 nm in diameter, with a negative sense ssRNA 
genome, composed of 3 segments, L (large), M (medium), and S (small), and enveloped 
in a host cell derived lipid bilayer envelope.   The L and M segments are negative in 
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polarity and respectively code for the L RNA-dependant RNA polymerase and a 
polyprotein precursor, which is cleaved into two envelope glycoproteins, G1 and G2, and 
two nonstructural proteins.  The S segment utilizes an ambisense strategy, coding for the 
nucleocapsid (N) protein in the antisense direction and the nonstructural protein (NSs) in 
the sense direction (Zeller and Bouloy, 2000). 
The three major structural proteins are the N protein and the two envelope 
glycoproteins, which project through the lipid bilayer.   The envelope glycoproteins are 
recognized by receptors on the surface of susceptible host cells, allowing for viral entry 
and antibodies produced by a host in response to RVFV infection are most often specific 
to the envelope proteins (Shimshony and Barzilai, 1983; Zeller and Bouloy, 2000).  
When the receptor binds virus glycoproteins, the virus is internalized by endocytosis and 
replication of the virus occurs in the cytoplasm.  Virions mature primarily by budding 
through the endoplasmic reticulum and golgi apparatus into cytoplasmic vesicles, which 
fuse with the plasma membrane to release the virus (Swanepoel and Coetzer, 1994).  
In order to be successful pathogens, viruses often utilize mechanisms to evade the 
host immune system.  In particular, many viruses have evolved a means of suppressing 
the type I IFN response (Haller et al., 2006).  The IFN response circuit is involved in 
various aspects of host immunity and the type I IFNs, IFN-β and multiple IFN-α 
subtypes, are major effector molecules in an antiviral response.  The NSs protein of 
RVFV demonstrates antagonistic activity to IFN (Billecocq et al., 2004; Bouloy et al., 
2001), thereby providing a means for the virus to establish infection.  During replication, 
NSs protein enters the cell nucleus and is responsible for the formation of filamentous 
eosinophilic inclusion bodies that are seen histologically during viral replication 
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(Shimshony and Barzilai, 1983).  These structures also contain subunits of the 
transcription factor TFIIH (Le May et al., 2004).  Le May and coworkers hypothesize that 
NSs prevents the assembly TFIIH complexes, leading to a dramatic decrease in cellular 
TFIIH concentration and general inhibition of cellular RNA synthesis during RVFV 
infection.  Billecocq and colleagues offered further evidence in support of this hypothesis 
by demonstrating that the IFN-antagonistic activity of NSs is not due to prevention of 
IFN-specific transcription factors, but rather to a general negative effect on the host cell 
transcription machinery, allowing the virus to indirectly circumvent the innate antiviral 
response (Billecocq et al., 2004).  More recently, NSs was shown to interact with host 
protein SAP30 (Sin3A Associated Protein 30) to repress IFN-β induction via binding of 
the transcription factor YY1 to a multiprotein repressor complex on the IFN-β promoter 
region, leading to the stabilization of the complex (Le May et al., 2008).  In either case, 
NSs seems to sufficiently repress IFN-β induction to allow RVFV to dampen the host 
immune response.  Attenuated RVFV strains containing mutations in the NSs region are 
less virulent in laboratory animals (Bird et al., 2008; Muller et al., 1995; Vialat et al., 
2000) and are better inducers of IFN than virulent strains (Bouloy et al., 2001).  Efforts 
toward vaccine development have exploited NSs gene mutations rendering the virus less 
virulent.  
 
Lack of prophylactic and therapeutic 
treatment underscores the need for 
continued research 
 
 Though some treatments and vaccines have been shown to be effective against 
RVFV in laboratory rodents and non-human primates, none are FDA-approved.  Both 
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live attenuated and formalin-inactivated vaccines are available for use in livestock, and 
formalin-inactivated vaccines have been developed for human use (Meadors et al., 1986; 
Sidwell and Smee, 2003).  A formalin-inactivated strain TSI-GSD-200 produced for 
livestock and human use (Pittman et al., 1999) possess protective qualities, but multiple 
vaccinations and boosters are required to maintain protection.  The live-attenuated 
Smithburn neurotropic vaccine strain was obtained after several mouse intracerebral 
passages of the virulent Entebbe strain. Though still in use as a veterinary vaccine, this 
strain retains some neurotropism and can produce complications in the central nervous 
system (Bouloy et al., 2001; Caplen et al., 1985).  Consequently, other attenuated strains 
have been produced or isolated, including MP-12 and clone 13.  The MP-12 strain was 
produced by Caplen et al. (1985) by 12 passages of the virulent Egyptian ZH548 strain in 
the presence of the mutagenic agent 5-flourouracil.  This strain contains multiple 
mutations in all three genome segments, that all contribute to attenuation (Saluzzo and 
Smith, 1990; Vialat et al., 1997).  Although this strain is immunogenic in animals, some 
harmful effects were observed when vaccinating pregnant ewes (Zeller and Bouloy, 
2000).  Isolated from a benign human case, clone 13 is naturally attenuated, containing a 
large deletion in the NSs gene-coding region, which leads to formation of a truncated 
protein (Muller et al., 1994a).  As previously discussed, NSs has IFN-inhibitory effects 
that make it crucial to virus evasion of the host immune response (Bouloy et al., 2001).  
This clone is apathogenic in mice and hamsters and confers long-lasting protective 
immunity in mice (Bouloy et al., 2001; Muller et al., 1995; Zeller and Bouloy, 2000).  
More recently, a lumpy skin disease virus-vectored recombinant vaccine expressing the 
two RVFV glycoproteins, G1 and G2, demonstrated the ability to induce neutralizing 
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antibody production and provide some protection against RVFV challenge in sheep 
(Wallace et al., 2006), and recombinant viruses containing deletions in the NSs and/or 
NSm genes conferred immunity in rats (Bird et al., 2008). 
Compounds with significantly inhibitory effects against RVFV include ribavirin 
(Peters et al., 1986), poly(ICLC) (Meadors et al., 1986; Peters et al., 1986) and 
recombinant interferon treatments (Morrill et al., 1989).  In one study, IFN was 
administered 24 hours prior to or 6 h after virus challenge, and was not as effective 
administered therapeutically as it was prophylactically.  While not FDA-approved for use 
against RVFV, ribavirin has been recommended for use under emergency provisions 
(Borio et al., 2002). 
 
Punta Toro virus as a model for acute  
phleboviral disease 
 As evident in this review of RVF, much is known of the nature of the disease and 
the etiological agent, but effective treatments for RVF are inadequate.  Though animal 
models based on the highly infectious RVFV have been described in rhesus monkeys, 
rats, gerbils, mice, and hamsters (Gowen and Holbrook, 2008; Sidwell and Smee, 2003), 
safety issues arise when working with RVFV in the laboratory because it is a BSL-3 
enhanced select agent and requires containment facilities not readily available to most 
researchers.  To this end, Punta Toro virus (PTV), a closely related BSL-2 classified 
Phlebovirus, has been employed as a surrogate virus to further investigate phleboviral 
disease and perform preclinical studies for potential therapeutic treatments in rodent 
model systems (Gowen et al., 2006a, 2006c, 2007, 2008; Pifat and Smith, 1987; Sidwell 
et al., 1988, 1992, 1994).   
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The Adames strain of PTV (PTV-A) has been shown to illicit disease in 
hamsters (Anderson et al., 1990; Fisher et al., 2003) and mice (Pifat and Smith, 1987) 
that is pathologically similar to that seen in RVFV-infection of domesticated livestock 
and humans.  However, Pifat and Smith (Pifat and Smith, 1987) observed disease only in 
4-week old mice, where 8-week mice only showed mild signs of illness and did not 
succumb to infection.  Several recent publications have reported the ability of PTV-A to 
cause fatal disease in adult C57BL/6J mice (Gowen et al., 2006a, 2007).  This 
discrepancy may be due to genetic differences in the PTV-A strains used.  
Comprehensive studies of disease pathology in tissues of 8-week old infected mice are 
needed. 
Although PTV-A is known to elicit disease in rodent models, the Balliet strain of 
PTV (PTV-B) does not induce disease in mice or hamsters (Anderson et al., 1990) when 
challenged subcutaneously, though PTV-B can cause disease in mice when injected 
intracranially (Sidwell et al., 1988) revealing the virus’s neurotropic nature.  Using 
reassortant viruses, Perrone and coworkers discovered that lethality is associated with the 
S segment of the virus (Perrone et al., 2007).  Moreover, the Adames strain inhibits type I 
IFN (IFN-α/β) induction, as well as activation of the IFN-β promoter.  These data 
suggest that the S segment of PTV-A encodes a protein that functions as an IFN-
antagonist, which is not present or is nonfunctional in PTV-B.  As discussed in greater 
detail below, type I IFNs initiate a signaling cascade that plays a critical role in the innate 
immune response to viral infection; thus, many viruses have evolved a means of evading 
these pathways and/or their effector molecules (Haller et al., 2006).  RVFV has such a 
mechanism mediated by the NSs protein, encoded on its S segment, which inhibits IFN-β 
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induction (Billecocq et al., 2004; Bouloy et al., 2001).  The inability of PTV-B to 
suppress IFN induction may explain why it does not produce lethal disease while PTV-A 
does. 
 
IFN signaling pathways 
   The type I IFN system serves a crucial function in the innate response to viral 
infection.  This point has been revealed in mice lacking a functional type I IFN receptor, 
which are far more susceptible to viral diseases (Bouloy et al., 2001; Bray, 2001; Haller 
et al., 2006; Muller et al., 1994b).  Further, mice with functional IFN receptor but lacking 
down-stream effectors in the IFN signaling pathway, such as Mx proteins or 2’-5’-
oligoadenylate synthetases (OAS) are similarly more susceptible to some viruses (Haller 
et al., 2006), as these proteins contain specific antiviral activities that are important to the 
host’s ability to control viral replication and spread.  Numerous recent reviews have 
focused on IFN pathways and the various signaling molecules that lead to the production 
of antiviral proteins (Edwards et al., 2007; Haller et al., 2006; Ozato et al., 2007; Pitha 
and Kunzi, 2007; Sadler and Williams, 2008; Samuel, 2001; Stetson and Medzhitov, 
2006).  There are two known distinct signal transduction pathways for detecting viruses 
and activating type I IFN genes (Haller et al., 2006).  The first is via intracellular RNA 
helicase proteins that sense viral components within the cytoplasm of infected cells.  
These sensors lead to the activation of IFN transcription factors IRF-3 and NF-kB, which 
transactivate the IFN-β promotor.  The second pathway is triggered by cell-surface or 
endosomal Toll-like receptors (TLRs) that activate IRF-7 to regulate IFN-α/β gene 
expression in plasmacytoid dendritic cells. 
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The intracellular detection pathway, also known as the classical pathway, is the 
most understood pathway for IFN-β gene expression in fibroblasts.  In infected cells, two 
non-redundant RNA helicases, RIG-I and MDA5 detect double-stranded (ds)RNA 
(Haller et al., 2006), a common replication intermediate.  RIG-I and MDA5 contain a 
caspase-recruitment domain (CARD) and signal to the recently discovered adaptor 
protein, virus-induced signaling adaptor (VISA) (Haller et al., 2006; Stetson and 
Medzhitov, 2006).  Though the downstream molecules interacting with VISA are not yet 
known, VISA indirectly leads to the activation of IRF-3 kinases by phosphorylation 
(Haller et al., 2006).  Phosphorylated IRF-3 in turn recruits other transcriptional 
coactivators to initiate transcription of IFN-β.  Similarly activated IRF-7 plays a crucial 
role in sustaining a positive feedback loop in which many IFN-α subtypes are produced 
(Honda et al., 2005; Marie et al., 1998).  IFN-β and the IFN-α subtypes activate a 
common type I IFN receptor, IFNAR, which signals via the JAK-STAT pathway (Haller 
et al., 2006).  Janus kinases (JAK) phosphorylate signal transducers and activators of 
transcription (STAT), which then recruit IRF-9 to form a complex known as IFN-
stimulated gene factor 3 (ISGF-3).  This complex translocates to the nucleus and 
promotes the transcription of IFN-stimulated genes (ISGs).   
IFNs regulate expression of hundreds of genes (Der et al., 1998), several of which 
have antiviral, antiproliferative, and immunomodulatory functions (Sadler and Williams, 
2008).  There are three particularly well-understood antiviral mechanisms stimulated by 
IFN: the dsRNA-dependent protein kinase R (PKR), the 2’-5’ OAS/RNase L system, and 
the Mx proteins.  PKR exhibits antiproliferative functions in preventing translation by 
phosphorylation of the initiation factor eIF-2α, thus inhibiting both cellular and viral 
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protein synthesis (Williams, 1999).  2’-5’ OAS produces oligoadenylates that activate 
RNase L to degrade RNA, also inhibiting protein synthesis.  Both PKR and 2’-5’ OAS 
are constitutively expressed at basal levels in inactive forms, but can be upregulated and 
activated through IFN signaling.  Mx genes, on the other hand are not normally expressed 
unless induced by IFN signaling (Haller et al., 2007).  The function of these proteins is 
not completely understood, though it has been shown that these proteins often bind 
essential viral components interfering with their function.  For example, MxA binds to 
the nucleocapsid (N) protein of bunyaviruses keeping the essential protein away from 
replication sites and therefore preventing proper viral assembly (Haller et al., 2007).   
Though these three pathways are the best understood, it is apparent from triple 
knockout studies in mice that they are not the only IFN-dependent antiviral mechanisms 
(Zhou et al., 1999).  Espert and others suggest a significant role for the ribonuclease 
ISG20 (Espert et al., 2003).  Their research revealed that ISG20 is inducible by IFN in 
mouse embryonic fibroblasts deficient in PKR, RNaseL, and Mx genes, and that 
constitutive expression confers resistance to RNA viruses.  They hypothesize that the 
ISG20’s mode of action is dependent upon it’s 3’-5’-exonuclease activity, as a single 
mutation within the ExoII exonuclease motif causes a dominant negative effect over the 
normal protein and allows better viral replication in cells expressing this mutant form.  
Other IFN-inducible proteins with potential antiviral properties are P56 (Guo et al., 
2000), guanylate-binding protein (GBP-1) and promyeloctyic leukemia protein (PML) 
(Haller et al., 2006).  RNA-specific adenosine deaminase 1 (ADAR1) also exhibits 
antiviral activity in its deamination of adenosine to yield inosine, altering protein coding 
and likely destabilizing dsRNA (Samuel, 2001).   
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In hamsters, the IFN-β response is modified by PTV-A resulting in decreased 
IFN-β induction (Perrone et al., 2007).  It is likely, though not certain, that the same is 
true in mice.  Here we wanted to study changes expression of IFN and related genes in 
response to infection with PTV strains, and due to reagent availability for mice but not 
hamsters, we utilized mouse-derived cells to accomplish our goals.  We examined the 
expression of various IFN and IFN pathway genes during the course of infection with 
PTV-A and PTV-B using quantitative RT-PCR technology. 
 
Quantitative PCR arrays for pathway  
gene expression analysis 
 In recent years, gene expression analysis has been utilized in various applications 
for multi-gene expression profiling and high throughput screening (Der et al., 1998; 
Lockhart and Winzeler, 2000).  Gene expression patterns can give powerful insight into 
understanding genetic mechanisms controlling a variety of processes, such as 
development, cancer progression, and host response to infectious disease.  Because we 
employed gene expression analysis in the form of qPCR arrays in this work, I will discuss 
in some detail the background and purpose for such methods.   
Proteins are responsible not only for morphology and phenotype, but also for 
changes in cell state and response to particular stimuli.  Since protein synthesis requires 
the initial step of transcribing genomic DNA to produce mRNA, changes in protein 
expression can often be implied through changes in mRNA levels, or gene expression 
levels. While measuring protein levels may be more accurate to understanding protein 
expression, these approaches are generally more difficult, less sensitive and inefficient 
compared to RNA approaches.  Furthermore, mRNA levels generally reveal a great deal 
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about cell state and gene activity, and for most genes, mRNA changes are directly 
related to protein changes (Lockhart and Winzeler, 2000).  In essence, mRNA detection 
can be used to cast a broad net to gather information for more specific complementary 
studies to verify results and further elucidate protein expression and/or activity.  
Although there are various methods for detecting and quantifying RNA for gene 
expression, including Northern blot, in situ hybridization, nuclease protection assays, 
differential display, cDNA sequencing, cDNA fragment fingerprinting, and serial 
analysis of gene expression (SAGE) (Bustin, 2000; Duggan et al., 1999; Giulietti et al., 
2001; Lockhart and Winzeler, 2000), the two most widely used technologies for gene 
expression profiling are hybridization-based microarrays and quantitative real-time RT-
PCR (qRT-PCR) analysis (Akilesh et al., 2003; Duggan et al., 1999; Giulietti et al., 2001; 
Lockhart and Winzeler, 2000).   
Microarray technology exploits basic molecular biology principles of nucleic acid 
complimentarity and recognition to detect the presence of a specific gene (Duggan et al., 
1999; Lockhart and Winzeler, 2000).  Gene expression levels are quantified using relative 
fluorescence between an experimental and control groups.  Microarrays can be used to 
evaluate tens of thousands of genes on a single chip in order to see a broad spectrum of 
genetic changes (Duggan et al., 1999; Lockhart and Winzeler, 2000). However, a large 
amount of RNA is required for hybridization (usually 50-200 µg) and fewer copies of a 
transcript result in lower probability of hybridization (Duggan et al., 1999).  Though it is 
possible to amplify RNA for microarray analysis (Bermudez et al., 2004), the methods 
can be difficult and add another source of error (Hart et al., 2004).  Consequently, 
microarrays often falter in the area of sensitivity.  Further, the microarray frequently 
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underestimates expression levels in comparison with qRT-PCR, sometimes leading to 
false negatives (Dallas et al., 2005; Gowen et al., 2009). 
As an alternative or validative technique to microarray analysis, though smaller in 
scale, qRT-PCR offers a highly sensitive, specific and relatively straightforward method 
for gene expression analysis (Provenzano and Mocellin, 2007).   Reverse transcriptase 
(RT)-PCR is useful in determining genetic regulation by measuring RNA, the 
intermediate messenger molecule produced from DNA in transition to protein.  Adding a 
quantitative aspect to RT-PCR (qRT-PCR) provides the ability to quantify the amount of 
RNA in one sample relative to other samples.  qRT-PCR relies upon fluorescent 
chemistry to quantify the amount of target present after each round of amplification.  
There are multiple methods for detection, including three that rely on the hybridization of 
a fluorescently-labeled complementary probe, and one fluorescent dsDNA-binding dye 
(Bustin, 2000).  In all cases, the amount of fluorescence signal increases with each 
amplifications cycle, indicative of increased amounts of target DNA (Bustin, 2000; 
Provenzano and Mocellin, 2007). 
In detecting target genes with low expression levels, such as cytokines or immune 
modulator proteins, it is important to use methods that are very specific and sensitive.  As 
reviewed by Giulietti et al., increasing amounts of data have conceded TaqMan probes to 
be highly specific and sensitive when used in qRT-PCR (Giulietti et al., 2001).  Such 
probes are designed for hybridization to a particular sequence within the PCR amplicon 
region, and the chemistry of the reaction is such that fluorescence only occurs after 
binding of the probe to its complementary region and subsequent hydrolysis via the 5’-
exonuclease activity of the Taq polymerase.  Other probe-based chemistries are also 
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available for qRT-PCR, including molecular beacons, scorpions, and hybridization 
probes, though these are not as commonly used or validated as is TaqMan chemistry 
(Giulietti et al., 2001).  The non-probe-based method for qRT-PCR utilizes the SYBR 
Green I dye, which incorporates into dsDNA and fluoresces only when bound to the 
dsDNA, but not when in free form (Giulietti et al., 2001).  Because of the non-specific 
nature of the dye, false positives may confuse data analysis, and it is therefore necessary 
to take additional precautions when using SYBR Green chemistry, such as careful design 
of primers, optimization of reaction conditions, use of Hot Start enzymes, and analysis of 
dissociation curves immediately following PCR (Arikawa et al., 2008; Giulietti et al., 
2001).  On the other hand, this chemistry is advantageous to probe-based strategies in that 
it can be used with primers for any target, making it less expensive and more universal.  
Investigations by Arikawa et al. (2008) revealed high concordance in results obtained 
using the widely accepted TaqMan method compared to the SYBR Green method, 
supporting the use of SYBR Green PCR as a suitable quantitative platform for gene 
expression studies.   
Quantitative PCR instruments detect the amount of target DNA using fluorescent 
dye chemistry.  The amount of product is recorded during every cycle as a function of 
fluorescence intensity (Bustin, 2000).  Amplification curves are generally sigmoidal in 
shape, with the exponential phase unveiling the number of cycles required to reach a 
certain intensity of fluorescence (Akilesh et al., 2003; Bustin, 2000).  The cycle threshold 
(CT) represents the number of amplification cycles required to reach threshold value 
assigned by the researcher.  Lower CT values mean fewer cycles required to reach the 
given threshold, hence, signifying the presence of more initial target cDNA in the 
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original sample.  Genes that do not amplify during the given number of cycles (usually 
40) are considered “off” and are given a CBTB value of 40 (Akilesh et al., 2003).  The CBTB 
does not denote the actual concentration of amplicon present.  It can only be used to 
compare changes across samples and to calculate fold-changes. 
In qRT-PCR, two methods of quantification are commonly used: the standard 
curve method and the comparative threshold method (Giulietti et al., 2001; Livak and 
Schmittgen, 2001).  The standard curve method involves generating samples of known 
concentration via purified plasmid dsDNA, in vitro-transcribed RNA, in vitro-
synthesized ssDNA, or any cDNA sample expressing the target gene (Giulietti et al., 
2001; Livak and Schmittgen, 2001).  Due to difficulties involved in obtaining and using 
these standards, this method is more often used only when absolute quantification is 
necessary.  In instances where it suffices to convey the change in expression as a fold-
change between an experimental and control sample, the comparative threshold method 
may be used to impart relative quantification (Giulietti et al., 2001; Livak and 
Schmittgen, 2001).  Relative values are calculated through changes in the CBTB between 
experimental and control groups.  The formula for calculating relative changes between 
groups is 2P-∆∆C PBTB, where ∆∆CBT B= ∆CBTB(experimental) – ∆CBTB(control), and ∆CBTB = 
CBTB(regulator gene) – CBTB(target gene).  For the 2P-∆∆C PBTB method to be valid, the amplification 
efficiencies of the target and regulator must be approximately equal.  Derivation of the 2 P-
∆∆C
PBTB method equation is discussed in detail by Livak and Schmittgen (Livak and 
Schmittgen, 2001). 
The regulator gene, or normalizer, is usually a housekeeping gene (i.e. GAPDH, 
β-actin, βB2B-microglobulin, and rRNA) that is used to account for differences between 
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total RNA loaded in each reverse transcription reaction.  Normalization is of utmost 
importance in qRT-PCR, as changes would be misinterpreted in the case that more total 
RNA is initially present.  However, overwhelming data have illustrated that a single 
housekeeping gene may not be the most reliable option for normalization.  GAPDH, β-
actin, and 18S rRNA have all demonstrated various levels of transcription in certain 
cases, leading to skepticism as to whether any of these provides a truly ideal regulator 
gene (Akilesh et al., 2003; Bustin, 2000; Provenzano and Mocellin, 2007).  In our 
research, we did not use one specific housekeeping gene to act as regulator gene, but 
instead employed Global Pattern Recognition software (Bar Harbor Biotechnology) to 
determine internal controls via genes that did not vary between sample groups.  This will 
be described in the next section in more detail. 
 
Global Pattern Recognition 
qRT-PCR technology employs primers specific to a gene of interest to detect even 
small amounts of RNA in a highly sensitive and reproducible manner, but it has been 
limited by practicality in the number of genes that can be evaluated (Akilesh et al., 2003).  
Recently, the development of quantitative PCR arrays has made it possible to investigate 
multiple genes, while maintaining the sensitivity of PCR (Akilesh et al., 2004; Akilesh et 
al., 2003; Brown et al., 2005; Chen et al., 2005; Hart et al., 2004; Ozaki et al., 2004).  Use 
of arrays containing various primer sets in each well of a 96- or 384-well plate allows 
researchers to examine a large number of genes in a single RNA sample simultaneously.  
Though still not reaching the incredible number of genes analyzed in a single microarray, 
these arrays can prove particularly valuable when research goals include investigating 
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genetic regulation in a specific known pathway.  For example in the work done here, 
we wanted to look at gene expression changes in IFN pathways throughout the course of 
infection with two different virus strains.  By using PCR arrays containing primers for 
IFNs and related genes, we were able to get a broad picture of genetic regulation within 
the IFN pathway.   
As previously mentioned, we utilized software from Bar Harbor Biotechnology to 
analyze our PCR array data.  This software comes standard with the purchase of their 
StellARray™ plates, and is used to generate fold-change and statistical significance 
values within a complete data set of a 96-well plate.  Although housekeeping genes are 
traditionally used in normalizing qPCR data, they are inherently inadequate in that they 
are always assumed to be invariant despite their inclination to fluctuate when comparing 
tissues or cells in different activation states (Akilesh et al., 2003).  In light of this, these 
researchers resolved to develop a more reliable system for normalizing data within their 
qPCR arrays, in which the comparison would not rely on a single normalizer gene.  They 
termed this novel statistical algorithm Global Pattern Recognition (GPR), due to its 
principle of establishing a pattern by comparing the expression of each gene to every 
other gene in the array.  Significant changes are identified and ranked and biological 
replicates are used to extract significant changes in gene expression.  In essence, GPR 
compares the CBTB of each gene individually with the CBTB of every other gene in the array 
that qualifies as a normalizer.  A detailed description of the GPR algorithm is available 
(Akilesh et al., 2003), though some modifications have been made since the original 
publication and information is proprietary.   Briefly, genes are filtered according to their 
ability to serve as a normalizer by sorting genes that do not reach a user-defined cycle 
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cutoff, meaning that all CBTB values of experimental and control groups for a given gene 
must fall below the cut-off value to pass through this filter.  Genes pass through a second 
filter for eligible genes if all observations in either control or experimental groups fall 
below the cycle cutoff value.  Filter groups are not exclusive, so genes may be in just one 
or both groups.  Each eligible gene is normalized to each eligible normalizer by 
computing a ∆CBTB value (CBTB(gene) – CBTB(normalizer)). Control and experimental groups 
are compared using a two-tailed unpaired t-test performed for each gene-normalizer 
combination, and a ‘hit’ is recorded if the p-value is below the user-defined value.  
Expectedly, significance is dependent upon which normalizer is used; so a GPR score is 
calculated as the fraction of normalizers that produced significant hits.  Through a series 
of experiments, Akilesh, Shaffer, and Roopenian (2003) demonstrated that if a gene 
shows statistically significant changes between groups when compared to >40% of 
eligible normalizers, the change is truly significant, while anything falling below the 40% 
mark cannot be deemed significant.  GPR has recently been employed in numerous 
publications (Akilesh et al., 2004; Bouma et al., 2004; Brown et al., 2005; Chen et al., 
2005; Hart et al., 2004; Ozaki et al., 2004; Seymour et al., 2007). 
 
 OBJECTIVES 
 
Because there is no data on the pathology of PTV in adult mice, we performed 
gross and histopathological examination throughout the course of infection with PTV-A 
and -B to assess disease parameters in parallel.  We examined liver, spleen, duodenum, 
adrenal gland, and brain tissues, as they are the affected organs in other disease models.  
We also looked at serum ALT, indicative of liver damage and virus titers.  In order to 
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determine the significance of IFN-β induction in protecting mice against lethal 
infection, we also quantified the amount of IFN-β in the serum of infected animals.  We 
tested the hypothesis that the IFN system is at least partially responsible for PTV-B’s 
inability to cause disease in adult mice.  Employing mice deficient in STAT-1, an 
essential protein to IFN signaling pathways (Akira, 1999; Haller et al., 2006), we 
observed the role of IFN-α/β in protecting mice against PTV infection.  We hypothesized 
that STAT-1 deficient mice would be susceptible to PTV-B-induced disease. 
We investigated genetic regulation of IFN signaling and response genes.  We 
measured growth efficiencies of both virus strains as well as IFN-β protein production by 
primary mouse macrophages in response to infection with either PTV-A or PTV-B.  We 
also examined mRNA changes of various IFN pathway-related genes throughout the 
course of infection using qPCR arrays and GPR software. 
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CHAPTER 2 
METHODS AND RESULTS 
 
 
Experimental Design 
 The first objective was to evaluate virologic and clinical disease parameters and 
tissue pathology in adult mice infected with PTV-A or PTV-B.  To accomplish this goal, 
groups of infected animals were sacrificed daily and sera, livers, spleens, small intestines, 
adrenal glands, and brains were harvested.  Virus titers were determined for each tissue.  
Sera were tested for the liver enzyme alanine aminotransferase (ALT), which is an 
indicator of liver disease.  IFN-β present in the serum of infected animals was quantified 
by ELISA.  Tissues were also examined for gross and histopathological changes. 
 IFN-antagonistic activity is thought to be a contributing factor to PTV-A’s 
pathogenicity in hamsters.  PTV-B is not assumed to exhibit this anti-IFN effect, as it 
stimulates earlier production of type I IFN in hamsters and induces IFN-β significantly 
better than PTV-A in hamster embryonic fibroblasts.  In order to assess the importance of 
the IFN response in PTV infection, 129S6 mice deficient in STAT-1 were infected with 
either virus strain.  Mice were monitored for signs of illness and tissues were harvested at 
the time of death for viral burden and serum ALT analysis.  In this way we were able to 
evaluate the role of the IFN response in mouse resistance to PTV-B.   
We sought to determine whether PTV-A’s IFN-antagonistic mechanism is 
functional in mice.  Primary macrophages from C57BL/6J mice were harvested and 
growth efficiencies of the two strains were determined in these cells.  Production of IFN-
β protein in macrophages was measured by ELISA.  RNA was collected at multiple time 
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points after infection and analyzed for changes over time in various IFN and related 
genes.  We employed quantitative PCR arrays specific to IFN signaling and response 
pathways to evaluate changes in IFN-related gene expression throughout the course of 
infection with either virus strain.  Comparisons of expression in PTV-A- versus PTV-B-
infected macrophages were made to determine the differences in gene regulation by each 
strain.   
  
MATERIALS AND METHODS 
 
Animals 
 Eight-week-old C57BL/6J mice were from Jackson Laboratories (Bar Harbor, 
ME) and 129S6/SvEv and STAT1 knockout (KO) mice (129S6 background) were from 
Taconic (Hudson, NY).  Animals were quarantined for 6 days prior to beginning studies 
in the animal facility at Utah State University under specific pathogen-free conditions.  
All animal procedures used in these studies complied with guidelines set by the U.S. 
Department of Agriculture and the Utah State University Animal Care and Use 
Committee. 
 
Cells and viruses 
Vero 76 (African green monkey kidney) and LLC-MK2 (rhesus monkey kidney) 
cells were from American Type Culture Collection (ATCC, Manassas, VA).  Cells were 
maintained in Minimal Essential Medium (MEM) supplemented with 10% Fetal Bovine 
Serum (FBS) or 5% FBS for Vero 76 and LLC-MK2 cells, respectively.  The Adames 
strain of PTV was provided by Dominique Pifat of the U.S. Army Medical Research 
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Institute for Infectious Diseases (USAMRIID, Frederick MD).  It was passaged 4 times 
in LLC-MKB2 B cells and once in hamsters.  The virus was originally isolated from the 
serum of a patient in eastern Panama in 1972.  The Balliet strain of PTV was from 
ATCC.  It was passaged twice in LLC-MKB2 B cells.  The Balliet virus was originally 
isolated from a patient in western Panama in 1966. Both virus strains were further 
passaged twice in Vero 76 cells.  Strains were verified by quantitative RT-PCR (data not 
shown).  Virus titers were performed in Vero 76 cells for determination of 50% cell 
culture infectious doses (CCIDB50 B).  All infections were performed in MEM supplemented 
with 2% FBS and gentamicin antibiotic (Sigma, St. Louis, MO).  All media, serum, and 
buffers were from Hyclone Laboratories (Logan, UT) unless otherwise stated. 
 Virus stocks were initially titrated in mice to determine the most appropriate 
infectious dose.  Based on these titrations, the 90-100% lethal doses (LD B90-100B) were 
chosen for subsequent challenge experiments discussed below.  All virus inoculations 
were by subcutaneous (s.c.) injection, unless otherwise indicated. 
For pathology and IFN analysis studies, C57BL/6J mice were challenged with 
2,000 CCIDB50B.  Groups of 7 mice were sacrificed daily, 3 PTV-A-infected, 3 PTV-B-
infected and 1 sham-infected.  Serum, liver, spleen, adrenal gland, and brain were 
collected from each.  A section of each tissue was fixed in formalin for at least 24 hours.  
The remaining portions of each tissue were stored at -80° until time of use for virus titer 
analysis.  Tissues were diluted and homogenized in MEM at weight/volume (g/ml) ratios 
based on tissue as follows: liver and brain at 1:10, and spleen and duodenum at 1:20.  
Due to the small size of the adrenal gland, accurate gram weights were unobtainable. 
Therefore, we added a set volume per tissue of 0.5 ml/adrenal gland.   
 30
For challenge studies in STAT1-deficient mice, 129S6 WT and STAT1 KO 
mice were challenged with 3.2 × 10P4 P CCIDB50 B of PTV and monitored for signs of illness 
and death.  Serum, liver, spleen, and brain were harvested from moribund animals for 
virus quantification.  Homogenization was performed as described above. 
 
Virus, ALT, and IFN-β quantification 
 Serum and homogenized tissue samples were diluted 1:10 and serial log dilutions 
were performed in MEM with 2% FBS and antibiotics.  Samples were plated on LLC-
MKB2 B cells for quantification of virus by determination of CCIDB50 B/ml or g.   
 Serum was diluted 1:10 in normal saline and ALT activity was measured in 
triplicate wells by kinetic assay using the ALT (serum glutamic pyruvate transaminase) 
reagent set (Pointe Scientific, Lincoln Park, MI).  The reagent volumes were adjusted for 
analysis on 96-well plates per the manufacturer’s specifications. 
IFN-β concentration in the serum samples was determined by specific enzyme-
linked immunosorbent assay (ELISA) (PBL Interferon Source, Piscataway, NJ) 
according to the manufacturer’s instructions.  All serum samples were diluted 1:5 or 1:10 
and tested in duplicate wells of the ELISA plate. 
 
PTV Growth in Vero 76 and PECs 
Mouse peritoneal exudate cells (PECs) were harvested by peritoneal lavage from 
C57BL/6J mice 4 days after intraperitoneal (i.p.) injection with 1 ml sterile aged 
thioglycollate (TG) broth.  Cells were plated in 96-well plates in RPMI with antibiotics.  
Two hours after plating, the nonadherent cells were removed by splashing off media and 
replacing with RPMI with 10% FBS and antibiotics. 
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Virus growth was determined in Vero 76 and PECs.   A multiplicity of 
infection (MOI) of ~0.0005 of PTV strains was used to infect cell monolayers.  
Supernatants were collected from triplicate wells on each day from 0-6 days p.i.  Samples 
were frozen and stored at -80°C until time of use.  Samples were plated on Vero 76 cells 
in serial log dilutions and virus CCID B50 Bs were determined. 
 
IFN induction and related gene  
expression in TG-elicited PECs 
 For IFN induction and gene expression studies, TG-elicited PECs were plated in 
96-well plates.  Cells were infected with ~3 × 10P3 P CCIDB50 B of each PTV strain (MOI of 
0.05).  Supernatants were collected from triplicate wells at 0, 2, 4, 6, 8, 12, 16, 24, 36, 48, 
60, 72, 84 and 96 hours p.i.  IFN-β in supernatants was quantified by ELISA. 
 At 0, 16, 24, 36, and 48 hours p.i., RNA was collected for use in gene expression 
studies with Qiagen’s (Valencia, CA) RNeasy Mini Kit following the manufacturer’s 
instructions.  Each sample contained RNA from 12 wells of a 96-well plate.  One µl 
Superase-In (Ambion, Austin, TX) was added to each 50 µl RNA sample to protect RNA 
from degradation.  Genomic DNA was eliminated using Ambion’s DNA free system.  
Quality of RNA samples was determined using Experion’s Automated Electrophoresis  
(Bio-Rad, Hercules, CA) at the Center for Integrated BioSystems (CIB, Utah State 
University, Logan, UT).  cDNA was synthesized from RNA samples using the 
Superscript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA).  Both oligo-dT 
primers and random hexamers were used in each synthesis reaction.  cDNA samples were 
diluted 1:20.  Interferon signaling and response StellARrays from Bar Harbor 
Biotechnology (Trenton, ME) were used to detect expression changes of multiple IFN-
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related genes simultaneously.  SYBR GreenER qPCR Supermix Universal (Invitrogen) 
was used in conjunction with StellARray plates for quantitative (q) real time PCR.  qPCR 
was performed in the Opticon 2 (Bio-Rad, Hercules, CA) thermal cycler using the 
following conditions: 95°C for 10 min, 40 cycles of 95°C, 60°C, followed by a 
dissociation curve reading every 1° C from 30°C to 95°C.  Global Pattern Recognition 
(GPR) software (Bar Harbor Biotechnology) was used to detect changes in gene 
expression levels.  
 
Statistics 
Survival curves were evaluated using log-rank analysis.  Two-way analysis of 
variance (ANOVA) was used to detect significance in overall difference between virus 
strain in growth curves and IFN-induction experiments and Bonferroni post-tests were 
performed to determine significance at individual time points.  
 
RESULTS 
 
PTV-A infection produces hepatic and  
splenic disease in adult mice 
A virus titration experiment was initially performed to determine the most 
appropriate dose for evaluating PTV disease in adult mice (Fig 1).  At viral challenge 
dose of 2 × 10P4 P fifty percent cell culture infectious doses (CCIDB50 B), 4 of 5 PTV-A-
infected animals succumb to the infection by day 7.  When challenged with 2 × 10P3 P 
CCIDB50 B of PTV-A, 100% mortality was observed by day 6 of infection.  At the lower 
inoculum (200 CCIDB50 B), only 2 of the 5 animals succumb to PTV-A-induced disease.  All 
animals challenged with equivalent dose of PTV-B survived.  On day 3 p.i, mice infected 
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Figure 1: Survival of C57BL/6J mice infected with PTV-A or PTV-B.  C57BL/6J mice 
were challenged subcutaneously with multiple doses of PTV-A or PTV-B (5 animals per 
group) and observed daily for mortality over a duration of 14 days.  Mice infected with 
PTV-A succumbed from disease, while those infected with PTV-B survived infection. 
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with PTV-A presented with clear signs of illness, such as weight loss, ruffled fur, 
hunching, and reluctance to move.  Mice showed no signs of illness prior to day 3 p.i., 
and by day 5 p.i., surviving mice seemed be on the road to recovery, showing milder 
signs of illness.  None of the animals infected with PTV-B gave any indication of illness 
regardless of viral inoculum.   
We next longitudinally evaluated various virologic and other disease parameters 
in mice challenged with the 2 × 10P3 P CCIDB50 B dose of PTV-A or -B by sacrificing groups of 
animals daily during the period of acute infection.  Upon gross examination, livers from 
PTV-A-infected mice began to look jaundiced, expressing a yellow-brown color on day 3 
p.i.  By days 4 and 5 p.i., the yellow color was much more pronounced and affected the 
entire liver (data not shown).  Livers of mice infected with PTV-B showed a slight 
change on days 4 and 5 p.i., but the change in color was very subtle. 
Histologically, the livers of PTV-A-infected mice appeared normal on days 1 and 
2 p.i.  By day 3 however, coalescing areas of severe, acute hepatocellular necrosis were 
apparent, and on day 4, necrosis became diffuse (Fig. 2A & C).  Clusters of remaining 
hepatocytes were swollen by numerous small intracytoplasmic vacuoles.  On day 5, 
hepatocytes demonstrated diffuse hydropic degeneration and individual necrotic cells 
were scattered throughout the lobules.  Hepatocellular necrosis was not present in mice 
infected with PTV-B, as liver sections appeared similar to those from sham-infected 
animals (Fig. 2B & D), though there was evidence of hypoxia in centrilobular 
hepatocytes on day 4 p.i. and mild hydropic degeneration on day 5 p.i (data not shown). 
 Similarly, spleens of PTV-A-infected mice were histologically normal on days 1 
and 2 p.i.  On days 3 and 4 p.i., lympholysis was present, characterized by cellular 
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Figure 2:  Pathology of PTV infection in mice.  (A) Liver of PTV-A-infected mouse on 
day 3 p.i.  Massive and diffuse hepatocellular necrosis is evident compared to (B) PTV-
B-infected animals, where tissues appear normal. (C) Magnification of day 3 liver during 
PTV-A infection.  (D) Liver from sham-infected animal.  (E) Day 4 spleen of PTV-A-
infected mouse shows lympholysis in the white pulp.  (F) PTV-B-infected animals had no 
pathological changes in the spleen (day 4).  All images are 40X magnification, with the 
exception of (C), which is 80X.
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fragmentation and nuclear pyknosis within periarteriolar sheaths (Fig. 2E).  Degenerate 
cells and macrophages containing hemosiderin and cellular debris were also scattered 
throughout the splenic interstitium.  On day 5 p.i., increased numbers of histiocytes and 
lymphocytes could be seen throughout the interstitium, and mild necrosis was seen in 
germinal centers.  Spleens of PTV-B-infected mice were histologically normal (Fig. 2F). 
Duodenums, adrenal glands, and brains of PTV-infected mice all appeared normal 
histologically, regardless of challenge virus strain (data not shown). 
We quantified systemic virus load by determining CCID50/ml of serum (Fig. 3A).  
In PTV-A infected C57BL/6J mice, systemic virus was undetectable on day 1 p.i. in all 3 
mice.  By day 2 p.i., two of three mice had infectious virus raising the mean titer to 4.5 
log10 CCID50/ml, and virus titers peaked on days 3 and 4 p.i. with 5.8 log10 CCID50/ml 
and 5.5 log10 CCID50/ml, respectively.  Serum virus was undetectable in the two 
surviving mice on day 5 p.i.  There was no detectable infectious virus in serum from any 
animals infected with PTV-B during days 1-5 p.i. 
Livers from 2 of 3 PTV-A-infected animals had detectable infectious virus on day 
2 p.i., reaching peak titers of  4.5 log10 CCID50/g (Fig. 3B).  On day 3 p.i., infectious liver 
virus was detectable in only one animal.  There was no detectable virus in samples taken 
on days 1, 4, or 5 p.i.  Livers from animals infected with PTV-B had no detectable virus 
on days 1-3 p.i.  However, 1 of 3 animals in each of the day 4 and 5 groups had virus 
titers of 5.3 log10 CCID50/g.  No virus was detected in spleens of PTV-infected animals 
on day 1 p.i. (Fig. 3C).  PTV-A-infected mice had splenic virus titers of 4.7 log10 
CCID50/g on day 2 p.i.  By day 3 p.i., spleen virus titers were high in all PTV-A-infected 
animals, averaging 6.8 log10 CCID50/g, and remained high (5.6 log10 CCID50/g) 
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Figure 3:  Mean virus titers in tissue samples from PTV-infected C57BL/6J mice.  Mice 
were challenged subcutaneously with PTV-A or PTV-B and groups of mice (3 per virus 
strain) were sacrificed daily on days 1-5 p.i. for collection of (A) serum, (B) livers, (C) 
spleens, (D) adrenal glands, (E) brains, and (F) duodenums.  Each tissue was analyzed for 
viral burden by determination of CCID50 in Vero 76 cells.  Values represent the means 
and SDs of groups of animals.  Due to mortality prior to day of sacrifice, data for the 
Adames strain on days 4 and 5 were from two mice.
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in spleens taken on days 4 and 5 p.i.  Splenic virus was also detectable in some animals 
infected with PTV-B on days 3-5 p.i. (Fig. 3C).  Though the serum and spleen harbored 
the greatest viral burdens, infectious virus was detectable in the adrenal glands of few 
animals infected with either PTV strain (Fig. 3D), and the brain of one animal infected 
with PTV-A (Fig. 3E).  There was no detectable infectious virus in the duodenum of 
animals infected with either PTV-A or PTV-B (Fig. 3F). 
 To assess liver damage, we also quantified systemic ALT in infected animals 
(Fig. 4).  Animals infected with PTV-A had baseline levels on days 1 and 2 p.i.  On day 
3, there was a pronounced spike in ALT, peaking at a mean concentration of 7000 IU/ml.  
Levels decreased in animals sacrificed on day 4 to 3400 IU/ml, and returned to near 
baseline levels by day 5.  Normal baseline ALT concentrations were present in PTV-B-
infected animals throughout the 5-day sampling period. 
 
PTV-B infection in mice does not induce  
systemic IFN-β 
Serum IFN-β levels were determined during the course of PTV infection by 
ELISA (Fig. 5).  In animals infected with PTV-A, no systemic IFN-β was detectable on 
day 1 p.i.  Mean IFN-β concentration reached 6460 pg/ml on day 2, where relatively high 
levels were present in two of three animals.  On day 3 p.i., all three animals had high 
serum IFN-β, averaging 7240 pg/ml.  Systemic IFN-β levels began to diminish by 4 and 
5 days p.i., with infected animals averaging 1990 pg/ml and 2045 pg/ml, respectively.  
IFN-β was undetectable in the serum on days 1-3 p.i. in animals infected with PTV-B.  
On day 4 p.i., two of three animals had barely detectable levels of IFN-β (~190 pg/ml).  
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Figure 4:  Serum ALT levels of C57BL/6J mice infected with PTV strains.  Mice were 
challenged subcutaneously with PTV-A or PTV-B and groups of mice (3 per virus strain) 
were sacrificed daily on days 1-5 p.i.  Serum was collected and ALT concentrations were 
determined.  ALT in serum serves as an indirect measure of liver injury.  Values 
represent the means and SDs of groups of animals.  Due to mortality prior to day of 
sacrifice, data for the Adames strain on days 4 and 5 were from two mice. 
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Figure 5:  Mean IFN in serum of PTV-infected C57BL/6J mice.  Mice were challenged 
subcutaneously with PTV-A or PTV-B and groups of mice (n=3 per strain) were 
sacrificed daily on days1-5 p.i. for collection of sera.  Serum IFN-β was determined by 
ELISA.  Values represent the means and SDs of groups of animals.  Due to mortality 
prior to day of sacrifice, data for the Adames strain on days 4 and 5 were from two mice.
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IFN-β was undetectable in animals sacrificed on day 5.  A similar experiment was 
performed by intraperitoneal (i.p.) route inoculation in attempt to achieve viremia and 
type I IFN induction in PTV-B-infected mice; however, results were similar to what was 
seen with s.c. injections with no systemic IFN-β (or viral burden) present in animals 
infected with PTV-B (data not shown).   
These results led us to question whether systemic induction of IFN played the 
same role in resistance to PTV-B infection in mice, as reported in hamsters (Perrone et 
al., 2007).  Although hamsters do not succumb to lethal disease upon infection with PTV-
B, they demonstrate elevated levels of circulating IFN-β compared to PTV-A-infected 
animals, which is thought to be the reason for resistance to PTV-B.  Since we observed 
very little to no IFN production by mice infected with the Balliet strain, we sought to 
investigate whether the IFN system was important for mouse survival of PTV-B 
infection.  We used STAT-1 knockout mice to determine whether the IFN signaling 
pathway plays a role in mouse resistance to PTV-B. 
 
IFN is required for protection against  
PTV-B infection 
 Unlike Adames, the Balliet strain of PTV is nonlethal and apathogenic in 
hamsters (Anderson et al., 1990; Perrone et al., 2007).  Here, we have shown that PTV-B 
is similarly nonpathogenic in adult mice.  These mice developed no physical signs of 
disease, and viremia was undetectable in serum from PTV-B-infected animals.  However, 
when mice deficient in STAT-1 were infected with PTV-B, 100% lethality was achieved 
(Fig. 6).  PTV-B-infected STAT-1 KO mice reached high infectious virus titers 
systemically and in the liver and spleen (Table 1).  No samples were taken from 129S6  
 42
 
 
Figure 6:  Survival of PTV-infected STAT-1 KO mice.  Mice were challenged 
subcutaneously with either virus strain and observed daily for mortality for a duration of 
14 days.  KO vs. WT survival data were compared for each virus strain by log-rank 
analysis and the resulting p-values were p=0.0058 for PTV-A,  p=0.0006 for PTV-B.  
Survival of PTV-A-infected KO mice differed significantly from that of PTV-B infected 
KO mice (p=0.0026)
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WT mice infected with PTV-B as none became ill during the course of infection.  
Because disease signs were absent, it was assumed that virus titers would be very low or 
undetectable in these animals, as is the case in C57BL/6J mice.  PTV-B-infected STAT-1 
KO mice also had high serum ALT, indicating that they were plagued with liver disease 
characteristic of phleboviral infection. 
In moribund animals sacrificed prior to death, WT PTV-A-infected mice had 
average serum, liver, and spleen virus titers of 6.1, 6.2, and 6.8 log10 CCID50/ml or g, 
respectively, while KO mice had titers of 9.2, 8.9, and 9.2 log10 CCID50/ml or g, 
respectively (Table 1).  Interestingly, KO animals infected with PTV-A also had high 
brain virus titers while WT animals had no detectable virus in the brain.  Similar high 
levels of serum ALT were observed at the time of death in PTV-A-infected WT and KO 
mice, though the comparable concentrations may have been due to saturation of the ALT 
assay leading to irresolution of differences between these groups of animals.   
Infectious virus was also assessed in WT and STAT-1 KO mice infected with PTV-A and 
sacrificed at the same time on day 3 p.i., thus allowing a direct comparison.  In this study, 
two KO and two WT mice were infected with PTV-A.  At the time of sacrifice, the 
infected WT mice showed some disease signs, such as ruffled fur and decreased 
movement, but to a much lesser degree than the KO mice.  We found that systemic and 
tissue virus titers were higher in KO animals infected with PTV-A compared to WT 
animals (Fig. 7).  Mean serum, liver, spleen and brain virus titers in KO mice were 9.2, 
9.0, 9.3, and 6.4 log10 CCID50/ml or g, respectively, compared to 6.3, 4.5, 6.5, and <2.7 
(below the threshold of detection) log10 CCID50/ml or g in WT mice.  One WT mouse 
had a liver virus titer of 6.7 log CCID50/g and 5,326 IU/ml serum ALT, while the  
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Table 1:  Disease parameter analysis in moribund STAT-1 KO vs. WT micea
Virus 
Strain 
WT/ 
KO 
Day 
p.i. 
Tissue Virus Titers ALT 
(IU/ml) 
      Serum           
(log10 
CCID50/ml) 
Liver            
(log10 
CCID50/g) 
Spleen         
(log10 
CCID50/g) 
Brain           
(log10 
CCID50/g) 
  
Adames WT 3 -c 6.5 7.0 <2.7d - 
Adames WT 3 5.8 <2.7d 6.5 <2.7d 6659 
Adames WT 3 6.3 6.2 6.5 <2.7d 6339 
Adames KO 3 -c 7.7 9.0 6.7 - 
Adamesb KO 3 8.5 8.7 8.8 5.7 6659 
Adamesb KO 3 9.5 9.2 9.5 6.7 6179 
Balliet KO 3 8.8 7.2 7.8 5.2 5539 
Balliet KO 5 6.8 6.7 7.0 3.5 1941 
Balliet KO 5 7.3 6.7 6.5 3.5 2306 
Balliet KO 8 <2.7d <2.7d 5.0 5.2 18 
 
a Animals were sacrificed when moribund.  Serum and tissues (liver, spleen, and brain) 
were collected for virus and ALT analysis. 
 b Two KO mice infected with PTV-A were 10 weeks old.  All others were 8 weeks of 
   age. 
 c Animal died before serum could be obtained. 
 d Infectious virus is below the limit of detection.
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Figure 7: Systemic and tissue virus and ALT in PTV-A infected STAT-1 KO vs. WT 
mice.  Two of each WT and STAT-1 KO mice were challenged subcutaneously with 
PTV-A and sacrificed on day 3 p.i.  Serum, livers and brains were harvested at the time 
of sacrifice and analyzed for viral burden (left panel) and ALT (right panel – serum only).  
Illness in STAT-1 KO mice was severe, while WT mice expressed only mild signs of 
illness at the time of sacrifice.  
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second had no detectable liver virus and baseline ALT levels, indicating that this 
mouse had not developed hepatic infection.  Serum ALT levels averaged 6,419 IU/ml in 
KO mice, as both mice had very high concentrations.  The purpose of this study was to 
obtain some insight into PTV-A viral burden and disease in STAT-1 KO and WT mice 
by direct comparison, as the limited number of animals did not allow for statistical 
analysis. 
 
PTV-B has a slight growth advantage in  
Vero 76 cells but not primary mouse  
macrophages 
 
In comparing growth rates of the two PTV strains, we found that PTV-A is slower 
to produce cytopathic effect (CPE) in interferon-incompetent Vero 76 cells (Emeny and 
Morgan, 1979; Mosca and Pitha, 1986) relative to PTV-B (data not shown).  To 
determine growth efficiency of the PTV strains, we infected Vero 76 monolayers with a 
low MOI of 0.0005 and collected supernatants each day out to 6 days p.i.  PTV-A titers 
increased through days 1-5 p.i., 2.0, 2.8, 5.2, 6.2, and 7.3 log10 CCID50/ml, respectively 
(Fig. 8A).  PTV-B titers measured 3.3, 5.5, 7.1, and peaked at 8.1 log10 CCID50/ml on 
days 1-4, respectively.  The amount of virus remained constant (~8.0 log10 CCID50/ml) 
after day 4 for PTV-B and day 6 for PTV-A.  Employing two-way analysis of variance, 
(ANOVA), we found that the difference in the growth curves was significant (p<0.0001), 
and Bonferroni tests comparing virus strains at each time point indicated significant 
differences on days 1-5 (p<0.05). 
No visual CPE was apparent in interferon-competent TG-elicited PECs infected 
with low doses of PTV strains.  Growth of both strains was most apparent during the first 
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Figure 8:  PTV growth in IFN-incompetent Vero 76 and IFN competent TG-elicited PEC 
cell cultures.  Cells were infected with an MOI of 0.0005 of either PTV-A or PTV-B.  
Supernatants were collected from triplicate wells on the indicated days p.i. and stored at -
80° C until time of use.  Virus titers were resolved by CCIDB50 B determination in Vero 76 
cells.  Growth curves in Vero 76 cells differed significantly by ANOVA (p<0.0001).  
Data are representative of three independent experiments with Vero 76 or PEC.  * p<0.05
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2 days of infection, reaching ~3.7 logB10B CCIDB50 B/ml on day 1 and peaking at ~4.6 logB10 B 
CCIDB50 B/ml on day 2 (Fig. 8B).  Titers were maintained from 4.0 to 4.5 logB10B CCIDB50 B/ml 
through the remaining sampling times.  Statistical analyses revealed no significant 
differences in growth efficiencies between the two virus strains in these cells.  
 
PTV-B evokes a potent IFN-β response  
in mouse primary macrophages  
We next investigated the induction of IFN-β by PECs infected with the PTV 
strains.  We collected samples for IFN-β analysis in a similar fashion as for growth curve 
determinations, but using a higher virus dose (MOI of 0.05) in order to get ample 
induction.  Supernatants from triplicate wells were collected every 12 hours from 0-84 
hours p.i.  Similar patterns of IFN-β expression were observed in the first 48 hours of 
infection, though concentrations were significantly (p<0.001) higher in PTV-B samples 
(Fig. 9).  We first saw IFN-β in supernatants beginning at 24 hours p.i.  At this time, 
PTV-B-infected PECs had produced ~14-fold more IFN-β than had PTV-A-infected cells 
(374 and 27 pg/ml, respectively).  IFN-β concentrations peaked at 36 hours p.i., reaching 
700 pg/ml in PTV-B samples and 133 in PTV-A samples (5.3-fold difference).  At 48 
hours, IFN-β levels in PTV-B samples had diminished and continued to decrease to 
through the remainder of the experiment.  Similarly, IFN-β fell in PTV-A samples at 48 
hours, and leveled out throughout the remainder of the time points.
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Figure 9:  IFN-β release by PTV-infected PECs.  Cell monolayers were infected with an 
MOI of 0.05 of either PTV-A or PTV-B.  Supernatants were collected from triplicate 
wells at the indicated time points and stored at -80° C until time of use.  IFN-β 
concentration was analyzed by ELISA.  Data are representative of results obtained in two 
independent experiments.  IFN-induction curves were analyzed by one-way ANOVA 
(p=0.0001) and Bonferroni post-tests revealed significance between samples from 24-84 
hours p.i. (* p<0.001) 
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PTV strain differences in stimulation of  
host interferon signaling and response  
pathways 
 
Although IFN-β production may not significantly impact growth in PECs, we know that 
without a functional IFN signaling through STAT-1 mice are unable to control PTV-B 
infection.  This led us to examine the genes involved in the IFN pathways that may 
contribute to host defense and their regulation in response to PTV-A and PTV-B 
infections.  We collected RNA from TG-elicited PECs infected with either strain and 
performed qRT-PCR on various IFN and related genes to determine changes in 
expression.  Though several genes in the IFN signaling and response pathways were 
influenced when primary mouse macrophages were infected with either PTV-A or PTV-
B (see supplemental data in appendix, Tables A-1-A-4 and Figs. A-1-A-4), Ifnb1 was the 
only gene that differed significantly (p=0.019) between cells infected with the two virus 
strains at 16 hours p.i., with PTV-B-infected macrophages having a 4.7-fold increase in 
expression compared to PTV-A-infected cells (Fig. 10).  Due to the high number of gene 
changes from time 0 to the time points examined, only the significant differences 
between the PTV-A and PTV-B groups will be discussed.  Complete information 
pertaining to overall genetic regulation during infection with a particular virus at each 
time point can be found in supplemental data tables and figures in the appendices section. 
 By 24 hours p.i., 16 genes varied significantly (p<0.05) between samples infected 
with PTV-A and PTV-B (Fig. 10).  Ifnb1 expression continued to be significantly greater 
in PTV-B (4.4-fold higher) compared to PTV-A infection.  Other genes that were induced 
at higher levels by PTV-B included multiple IFN-α subtypes, Ifna1 (4.3-fold), Ifna2 (3.8-
fold), Ifna5 (4.7-fold), and Ifnab (8.6-fold), interferon-inducible proteins, Isg20 (1.9-fold) 
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Figure 10:  Expression patterns over time of genes with significant differences between 
PTV-A and PTV-B-infected macrophages at one or more time points.  PECs were 
infected with a MOI of 0.05 and RNA was collected at the indicated time points.  
Samples were analyzed by qRT-PCR for gene expression.  Fold-change represents the 
change in gene expression from time 0 to the indicated time point.  *p<0.05 
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Figure 10 (continued):  Expression patterns over time of genes with significant 
differences between PTV-A and PTV-B-infected macrophages at one or more time 
points.  PECs were infected with a MOI of 0.05 and RNA was collected at the indicated 
time points.  Samples were analyzed by qRT-PCR for gene expression.  Fold-change 
represents the change in gene expression from time 0 to the indicated time point.  
*p<0.05 
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and Iigp1 (2.7-fold), and inflammatory molecules such as Cxcl10 (5.3-fold), Cxcl11 
(6.8-fold), Il6 (5.4-fold), Vcam1 (3.2-fold), and Socs1 (2.5-fold).  Expression of Tnfsf10 
(2.1- fold), a gene product that induces apoptosis, is also significantly higher in PTV-B 
infection.  Genes whose expression was comparatively lower in PTV-B samples included 
Ifngr (-2.1-fold), Rb1 (-1.7-fold), and D430028G21Rik (VISA) (-1.8-fold).  At 36 hours 
p.i., six of the genes mentioned above continued to exhibit increased expression in PTV-
B samples (Fig. 10).  These included Cxcl10 (3.4-fold), Iigp1 (2.5-fold), Socs1 (2.4-fold), 
Cxcl11 (5.3-fold), Il6 (8.4-fold), and Vcam1 (3.2-fold).  Cxcl9 also demonstrated 
increased expression in PTV-B infected cells at 36 hours with a fold change of 2.8 
compared to PTV-A.  At 48 hours p.i., Cxcl11 was the only gene which continued to be 
significantly upregulated (4.4-fold) in PTV-B samples compared to PTV-A (Fig. 10).  
However, Ifi203 and Myc both demonstrated decreased expression of -2.2- and -2.9-fold, 
respectively. 
Genes demonstrating differential expression between PTV-A- and PTV-B-
infected cells at 24-hours p.i., were analyzed with IPA software to reveal connectivity of 
these genes to each other, as well as genes not included in the analysis.  A network of 
interconnected immune response genes was generated containing all but three of the 
genes differentially stimulated by the two virus strains at that time point (Fig. 11). 
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Figure 11:  Network of immune response genes associated with genes differentially 
expressed between PTV-A and PTV-B-infected macrophages at 24 hours p.i.  Ingenuity 
Pathways Analysis software was used to analyze datasets at the 24-hour time point and 
generate networks centered on genes with significant differential expression.  Red 
indicates increased and green indicates decreased expression in PTV-B-infected 
macrophages compared to PTV-A, with magnitude of differences specified by color 
intensity.  Gray indicates genes that were included in the analysis but were not 
differentially expressed.  White indicates genes that were not included in the analysis. 
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CHAPTER 3 
CONCLUSIONS 
 
RVFV has been responsible for multiple epidemics in sub-Saharan Africa, Egypt, 
Saudi Arabia, and Yemen (CDC, 2000a, 2000b; Swanepoel and Coetzer, 1994), causing 
disease in domesticated livestock, as well as humans.  In the event of release into the 
U.S., the virus could have great agricultural and public health impacts if it were to 
establish itself in the environment.  The need for further research into the disease process 
and the development of prophylactic and therapeutic interventions is clear; however, 
RVFV requires enhanced BSL-3+ containment not readily available to most researchers.  
Therefore, the use of a less hazardous model of phleboviral disease has been developed.  
PTV has proven to serve in this capacity modeling acute hepatic disease caused by RVFV 
for study of disease pathogenesis and potential countermeasures (Gowen and Holbrook, 
2008).  Though PTV-induced disease in hamsters has been well-characterized (Anderson 
et al., 1990; Perrone et al., 2007), few reagents are available for the hamster model, so we 
sought here to further evaluate the disease in adult mice.   
Pathological findings in the 8-week-old mice were similar to those reported 
previously in PTV-A-infected weanling mice (Pifat and Smith, 1987).  We observed 
hepatocellular necrosis in the liver, as well as lympholysis in the spleen.  The timing of 
the observed pathological changes corresponds to that seen in 4-week mice, with lesions 
developing by day 3 p.i. and progressing through day 4.  PTV-A-induced disease in 
hamsters transcends the liver, particularly affecting the duodenum and causing severe 
enteritis that is thought to be the primary pathogenic lesion (Anderson et al., 1990).  No 
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pathological changes were observed in the duodenum of infected mice in the current 
study, although mild necrosis was observed in the small intestines of 4-week-old animals 
(Pifat and Smith, 1987).  As previously described, the splenic lesions in hamsters are 
localized to the red pulp (Anderson et al., 1990), while we observed lympholysis in the 
white pulp of mice, consistent with previous findings in 4-week-old animals (Pifat and 
Smith, 1987).  The disease pathology, however, models that seen in natural RVFV 
infections of domestic livestock and humans (Swanepoel and Coetzer, 1994), with the 
liver being affected most dramatically by PTV-A infection in the older mice.  
Although the Eastern Panamanian PTV-A strain causes a lethal disease in 
hamsters and mice, the Balliet strain, isolated in Western Panama, is nonlethal in both 
small animal models (Anderson et al., 1990; Sidwell et al., 1988).  We found that PTV-B 
does not replicate to detectable limits systemically, though low viral titers are detectable 
in the liver and spleen of some animals.  This contrasts the measurable viral burden in 
hamster blood during the course of infection (Perrone et al., 2007).  Further, baseline 
ALT levels are present in PTV-B infected animals, indicating that the virus is not causing 
damage to the liver such as the Adames strain. 
In PTV-A-infected animals, ALT levels lagged behind liver virus titers, which 
peaked on day 2 p.i.  Further, liver virus titers were notably low considering the amount 
of pathological damage and high systemic ALT levels observed.  These observations 
suggest a possible immunopathological mechanism involved in PTV-A-induced disease. 
This hypothesis is supported by studies wherein toll-like receptor 3 (TLR3) deficient 
mice were found to be more resistant to PTV-A challenge (Gowen et al., 2006b).  
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Compared to WT mice, the vigorous proinflammatory cytokine responses that may 
contribute to disease severity were less profound in the TLR3 KO mice. 
There are obvious disparities in pathogenic mechanisms between the Adames and 
Balliet strains of PTV, which are thought to be at least partially attributed to modulation 
of the host immune response by PTV-A.  Similar to RVFV (Billecocq et al., 2004; 
Bouloy et al., 2001), PTV-A contains a protein coded on its S segment that exhibits IFN-
antagonistic activity in the hamster system by repressing activation of the IFN-β 
promoter (Perrone et al., 2007).  Mouse derived macrophages also demonstrate a subdued 
IFN-β response to infection with PTV-A when compared to PTV-B-infected 
macrophages.  This IFN-antagonistic activity likely plays a significant role in 
pathogenicity of PTV-A in both hamsters and mice, and PTV-B’s lack of anti-IFN 
activity is likely the principal reason it is unable to cause disease in these models.  It is 
probable that PTV-A’s IFN-antagonistic activity functions similarly in both models, and 
likely in the same way as RVFV’s NSs protein.   
One key difference in the mouse and hamster models is that PTV-B induces no 
detectable systemic IFN-β in mice, while animals infected with PTV-A presented with 
high systemic IFN-β concentrations starting on day 2 and peaking on day 3 p.i.  This is 
likely due to the lack of PTV-B dissemination into the blood.  In PTV-infected hamsters, 
PTV-B induces type I IFN earlier during infection than PTV-A, with similar titers 
reached by 72 hours p.i. (Perrone et al., 2007).  Notably, in contrast to mice, PTV-B 
infection in hamsters does reach detectable viral loads in the blood.  Thus, it is not 
surprising that an animal that has little to no systemic virus would not elicit a high level 
of circulating IFN.  We believe that due to a more effective IFN response to PTV-B at the 
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site of s.c. inoculation, animals are able to control the virus locally before viremia is 
achieved.  In an attempt to produce a systemic infection to evoke a better IFN response, 
we also tried i.p. inoculation, but still detected no circulating virus suggesting that PTV-B 
was effectively controlled in the peritoneal cavity by resident immune cell populations. 
STAT-1 is a key component in the IFN signaling pathway (Akira, 1999; Haller et 
al., 2006), and therefore, eliminating its function effectively knocks out the IFN response 
circuit.  To this end, our findings rendering mice that are lacking in this pathway 
susceptible to PTV-B infection indicate that the virus is controlled principally by the type 
I IFN response since WT mice do not develop disease.  However, pathogenic differences 
between PTV-A and PTV-B are not completely attributable to regulation within the IFN 
response circuit, as STAT-1 deficient animals challenged with PTV-A succumbed to 
infection on average >2 days earlier than those challenged with PTV-B (p=0.0026).  In 
fact, even WT mice challenged with PTV-A succumbed earlier than did KO mice 
challenged with PTV-B (p=0.0058).  Moreover, KO mice infected with PTV-A 
succumbed to severe PTV infection in less time and developed higher viral burdens 
compared their WT counterparts.  These data suggest that additional mechanisms are also 
responsible for PTV-A’s increased pathogenicity in mice. 
Although IFN-β production was significantly decreased in macrophages infected 
with PTV-A compared to PTV-B, there was still detectable IFN-β protein, as well as 
significantly increased levels of IFN-β and IFN-α subtypes mRNA at 16 and 24 hours 
p.i. (Appendix A).  Further, in mice infected with PTV-A, systemic IFN-β was detectable 
as early as 2 days p.i.  Collectively, our studies indicate a suppressed IFN response to 
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PTV-A infection in mice, which is consistent with what was observed in hamsters 
(Perrone et al., 2007). 
In previous work by Perrone and coworkers, neither strain had a growth 
advantage in interferon-incompetent cells, but PTV-A had an obvious advantage in 
interferon-competent hamster embryonic fibroblasts (Perrone et al., 2007).  Notably, 
experiments by Perrone et al. were done in Vero cells and experimental methods differed 
somewhat from ours, including the use of 20-fold greater MOIs.  Though similar PTV 
strains were used in our work, differences in passage history may have also contributed to 
the difference we observed in Vero 76 cells.  Our strain of PTV-A was passaged once 
through hamsters prior to the generation of our stock in Vero 76 cells.  Therefore, our 
strain of PTV-A may not be as well suited for growth in vitro, compared to PTV-B, 
having always been passaged in monkey kidney cells.  We found however that there is no 
significant growth difference between a PTV-A stock that has been passaged strictly in 
cell culture and the one used in our studies that has been through hamsters (data not 
shown). 
Though we anticipated that PTV-A would have a growth advantage in primary 
mouse macrophages, as it does in hamster embryonic fibroblasts (Perrone et al., 2007), 
this was not the case.  The PTV-B growth advantage in IFN-incompetent Vero 76 cells 
was not borne out in the mouse primary inflammatory macrophages, as we observed 
similar growth patterns for both strains in TG-elicited PECs.  PTV-B stimulates early 
IFN-β induction in hamster embryonic fibroblasts, approximately two-fold higher than 
PTV-A (Perrone et al., 2007), leading to reduced viral replication.  It would seem 
probable that since PTV-B is a better inducer of IFN in PECs that its growth would be 
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inhibited compared to PTV-A.  The loss of PTV-B growth advantage in IFN-
incompetent Vero 76 cells may be due to the effect of higher IFN induction in PTV-B-
infected cells.  The more restricted viral replication observed in macrophages suggests 
that these cells are not as accommodating to PTV growth as fibroblasts.  To this end, it is 
not surprising that the previously reported growth advantage of PTV-A in hamster 
embryonic fibroblasts did not correlate with our findings in mouse macrophages since 
these are vastly different cell types. 
To more fully understand the mechanisms involved in resistance to PTV-B, we 
examined expression of a variety of IFN and related genes in mouse macrophages.  We 
found that regulatory mechanisms of IFN-β production likely occur at or before the gene 
transcription level, as there is a significant >4 fold increase the amount of IFN-β RNA in 
macrophages infected with PTV-B compared to PTV-A at 16 hours p.i.  This is consistent 
with previous findings by Perrone and colleagues that showed a ~3-fold increase in the 
IFN-β promoter by PTV-B (Perrone et al., 2007).  By comparison, IFN signaling 
pathways are down-regulated at later time points in PTV-A-infected macrophages, 
particularly 24 and 36 hours p.i.  Multiple genes encoding IFN-α subtypes were induced 
3-9-fold higher in PTV-B-infected cells at 24 hours p.i.  
PTV-B-infected macrophages also demonstrated increased transcription of a 
number of proinflammatory cytokines and chemokines compared to PTV-A-infected 
cells.  In vivo, these molecules could lead to early and localized control of the virus, 
preventing dissemination.  Il6, Cxcl9, Cxcl10, and Cxcl11 code for inflammatory proteins 
that can contribute to temperature modulation and leukocyte migration to the site of 
infection.  CXCL proteins are chemotactic molecules that attract immune cells to the site 
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of infection.  Cytokine-induced vascular cell adhesion molecule 1 (VCAM-1) is known 
to promote adhesion of leukocytes to vascular endothelium (Ou et al., 2008).  As 
demonstrated by gene deletion studies, expression of VCAM-1 is critical for proper 
leukocyte migration and regulation of inflammatory response in viral infection (Ou et al., 
2008).  We found that these molecules were expressed at higher levels in macrophages 
infected with PTV-B compared to those infected with PTV-A, which indicates a stronger 
proinflammatory response elicited by PTV-B.  
We did not see significant transcriptional changes in the most commonly known 
IFN response genes, such as Eif2ak2 (PKR), Oas, or Mx genes, as a result of increased 
levels of type I IFNs early in infection with PTV-B.  However, Isg20 was expressed ~2-
fold higher in PTV-B-infected macrophages than PTV-A at 24 hours p.i. (p<0.05).  Isg20 
is the second known RNase, along with RNaseL, to be regulated by interferon (Nguyen et 
al., 2001) and its expression can be regulated by IFNs in PKR-, RNase L- and Mx-
deficient fibroblasts, demonstrating an independent regulatory mechanism from these 
common IFN-induced molecules (Espert et al., 2003).  Isg20 possesses antiviral 
properties against RNA viruses, specifically vesicular stomatitis virus, influenza, and 
encephalomyocarditis viruses, but not the DNA genomic adenovirus (Espert et al., 2003).  
As Isg20 does not require functional PKR, RNase L, or Mx proteins, it is assumed to 
serve as an alternative antiviral pathway to those already well-described.  In the case of 
PTV, a ssRNA virus, this alternative pathway may provide the means of host control of 
PTV-B infection.  Studies utilizing technology to knock-down Isg20 expression in mice 
would best answer the question as to whether this protein plays an important role in the 
host response to PTV infection.  
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Also of interest, Iigp1 (interferon-inducible GTPase 1) transcription was found 
to be upregulated ~2.7-fold at 24 hours p.i and ~2.4-fold at 36 hours p.i., (p<0.05) in 
response to infection of PECs with PTV-B compared to PTV-A.  Iigp1 codes for a 
protein belonging to a family of 47-kDa GTPases whose members are present at low 
basal levels in mouse cells but are induced by IFNs and are implicated in resistance to 
intracellular pathogens (Carlow et al., 1998; Uthaiah et al., 2003; Zerrahn et al., 2002).  
Though the function of these GTPases is unknown, data support their involvement in 
defense against intracellular pathogens and the protective mechanism is likely effective 
during the early innate immune response (Collazo et al., 2001; Taylor et al., 2000; 
Zerrahn et al., 2002).  The importance of some of these GTPases has been demonstrated 
by their role in bacterial resistance (Collazo et al., 2001; Taylor et al., 2000) and their 
antiviral activity against the ssRNA virus, vesicular stomatitis virus (Carlow et al., 1998), 
but not the DNA viruses, murine cytomegalovirus and herpes simplex virus (Carlow et 
al., 1998; Collazo et al., 2001; Taylor et al., 2000).  The function of IIGP1 in host 
antiviral defense has not yet been assessed, but IIGP1 shares several similar biochemical 
properties to other known GTPases with antiviral activities against ssRNA viruses, such 
as the Mx proteins (Uthaiah et al., 2003).  The human protein MxA interferes with RVFV 
replication, allegedly through association with the viral RNA polymerase (Carlow et al., 
1998). 
As elucidated in these studies, IFN plays a critical role in survival of mice 
infected with PTV-B.  These results imply that IFN could be effective in treatment of 
phleboviral disease.  A recombinant IFN-α, Interferon alfacon-1, demonstrates 
appreciable efficacy against PTV infection in hamsters when given up to 72 hours after 
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infection (Gowen et al., 2008).  Further, recombinant IFNs have proven effective 
against RVFV in rhesus monkeys when administered 24 h prior to, or 6 h after infection 
(Morrill et al., 1989).  Though these results suggest that therapeutic IFN intervention 
would be useful in treating phleboviral disease, efficacy appears to require early 
intervention, and cost associated with recombinant IFN treatments would likely be 
prohibitive for use in remote underdeveloped areas the world where RVF is endemic.  
Nevertheless, treatments targeting the stimulation of the IFN pathway could prove to be 
particularly effective against phleboviral infection, and should continue to be explored.  
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Table A-1: Expression of IFN and related genes at 16 hours p.i.  Fold change is 
relative to gene expression at time 0. 
GENE ID ADAMES BALLIET 
 Fold Change p-value Fold Change p-value 
 Adar 2.8 0.017  3.2 0.040 
 Ciita -1.5 0.030  -1.3  NS 
 Cxcl10 78.4 0.007  243.3 0.007 
 D430028G21Rik -1.8 0.022  -1.5  NS 
 Eif2ak2 3.4 0.038  3.7 0.029 
 Eif4g2 -1.6 0.041  -1.0  NS 
 Fas -1.5 0.024  1.0  NS 
 Ifi203 3.1  NS 4.8 0.036 
 Ifi204 6.1 0.015  8.2  NS 
 Ifi27 4.8 0.015  4.9 0.060 
 Ifi35 2.7 0.011  3.7 0.028 
 Ifi44 123.9 0.002  158.5 0.013 
 Ifi47 13.6 0.006  18.4 0.018 
 Ifih1 3.5 0.011  5.4 0.032 
 Ifit1 137.3 0.011  236.1 0.001 
 Ifit2 169.2 0.010  284.2 0.002 
 Ifit3 154.1 0.001  237.3 0.005 
 Ifitm3 4.0 0.020  4.0  NS  
 Ifna5 14.2 0.006  28.6 0.014 
 Ifnar1 -1.7 0.030  -1.2  NS 
 Ifnar2 -2.1 0.018  -1.4  NS  
 Ifnb1 12.9 0.005  72.1 0.005 
 Ifngr1 -2.0 0.020  -1.9  NS 
 Igtp 5.4 0.008  7.1 0.049 
 Iigp1 17.3 0.034  29.0 0.020 
 Iigp2 9.6 0.016  11.2 0.007 
 Irf1 4.6 0.034  5.1 0.032 
 Irf7 22.4 0.006  27.0 0.013 
 Irf8 -1.8 0.021  -1.7  NS 
 Irf9 1.5 0.022  1.7  NS 
 Isg20 12.0 0.008  20.1 0.029 
 Mx1 57.3 0.008  126.6 0.003 
 Oas1b 8.6 0.009  11.0 0.014 
 Oas2 13.9 0.021  17.1 0.009 
 Pias1 -1.5 0.030  -1.1  NS 
 Psmb9 1.6 0.025  2.1  NS  
 Psme1 1.5 0.047  1.8  NS 
 Rb1 -1.9 0.014  -1.5  NS 
 Sfpi1 -1.8 0.015  -1.4  NS 
 Socs1 5.5 0.009  9.9 0.032 
 Spp1 -1.8 0.014  -1.2  NS 
 Stat1 4.9 0.008  5.6 0.041 
 Stat2 9.1 0.009  8.8 0.017 
 Tap1 4.2 0.019  4.2 0.031 
 Ticam1 -1.8 0.032  -1.6  NS 
 Tlr7 1.4 0.027  1.8  NS 
 Tnfsf10 23.8 0.005  42.2 0.012 
 Trim21 2.8 0.044  3.5  NS 
 Vcam1 6.3 0.011  9.4 0.023 
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Table A-2: Expression of IFN and related genes at 24 hours p.i.  Fold change is 
relative to gene expression at time 0. 
GENE ID ADAMES BALLIET 
 Fold Change p-value Fold Change p-value 
 Adar 1.7 0.008 1.5 0.005 
 Ciita -2.7 0.013 -4.0 0.006 
 Cxcl10 232.0 0.005 1355.7 0.002 
 Cxcl11 5.7 0.004 41.4 0.003 
 Cxcl9 9.9 0.007 15.4  NS 
 D430028G21Rik -4.2 0.010 -7.0 0.003 
 Eif2ak2 2.3 0.018 2.3 0.013 
 Eif4g2 -3.6 0.017 -5.8 0.006 
 Fas -2.1 0.018 -1.0 0.004 
 H2-D1 -3.0 0.012 -2.3 0.005 
 Hdac1 -2.3 0.010 -2.1 0.006 
 Ifi204 6.2 0.032 4.7 0.011 
 Ifi27 7.1 0.010 6.1 0.005 
 Ifi30 -3.7 0.008 -4.8 0.006 
 Ifi35 2.3 0.006 3.2 0.003 
 Ifi44 353.1 0.001 512.1 0.001 
 Ifi47 14.9 0.002 17.3 0.002 
 Ifih1 3.5 0.006 5.6 0.005 
 Ifit1 120.4 0.009 159.9 0.007 
 Ifit2 232.7 0.010 273.5 0.010 
 Ifit3 224.5 0.001 339.8 0.001 
 Ifitm3 3.8 0.012 3.9 0.007 
 Ifna1 4.8 0.004 21.5 0.005 
 Ifna2 3.0 0.006 12.0 0.003 
 Ifna4 8.6 0.018 26.4 0.002 
 Ifna5 25.0 0.002 126.7 0.001 
 Ifnab -1.2  NS 7.8 0.003 
 Ifnar1 -3.8 0.009 -3.2 0.008 
 Ifnar2 -3.4 0.012 -3.5 0.008 
 Ifnb1 45.5 0.001 211.4 0.001 
 Ifngr1 -5.4 0.007 -10.6 0.002 
 Ifngr2 -2.7 0.015 -3.3 0.007 
 Igtp 6.6 0.006 10.6 0.003 
 Iigp1 43.9 0.017 123.2 0.016 
 Iigp2 7.8 0.014 11.0 0.009 
 Ikbke -1.8 0.015 -1.6 0.009 
 Il10rb -2.8 0.012 -3.3 0.012 
 Il4ra -2.1 0.016 -2.5 0.009 
 Il6 4.6 0.030 26.3 0.002 
 Il6st -4.0 0.007 -5.0 0.004 
 Irf1 2.8 0.030 4.3 0.017 
 Irf2 -2.2 0.012 -2.0 0.007 
 Irf3 -2.8  NS -4.4 0.029 
 Irf4 3.2 0.019 -3.6 0.013 
 Irf5 -2.6 0.009 -2.3 0.005 
 Irf7 31.0 0.006 43.1 0.005 
 Irf8 -2.9 0.015 -4.1 0.010 
 Irf9 -1.2 0.009 -1.6 0.008 
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Table A-2 (continued): Expression of IFN and related genes at 24 hours p.i.  Fold 
change is relative to gene expression at time 0. 
GENE ID ADAMES BALLIET 
 Fold Change p-value Fold Change p-value 
 Isg20 28.0 0.002 59.2 0.002 
 Jak1 -2.8 0.008 -3.3 0.006 
 Jak2 -1.0 0.009 1.6 0.005 
 Mx1 79.2 0.005 90.6 0.004 
 Mx2 49.8 0.003 74.0 0.002 
 Myc -5.2 0.018 -6.6 0.014 
 Oas1b 7.1 0.006 9.4 0.005 
 Oas2 10.1 0.021 9.9 0.015 
 Pias1 -3.0 0.009 -3.5 0.007 
 Psmb9 1.5 0.007 1.9 0.007 
 Rb1 -5.8 0.003 -9.5 0.001 
 Rn18s -2.9  NS -4.4 0.047 
 Rnasel -1.5 0.010 -1.7 0.006 
 Sfpi1 -3.4 0.008 -4.2 0.004 
 Socs1 6.7 0.008 18.0 0.003 
 Spp1 -4.8 0.006 -4.7 0.004 
 Stat1 4.0 0.004 4.7 0.003 
 Stat2 5.8 0.012 6.5 0.007 
 Tap1 3.5 0.014 4.8 0.007 
 Tgfb1 -3.5 0.015 -3.8 0.009 
 Ticam1 -4.3 0.012 -5.0 0.007 
 Tlr9 3.1  NS 5.5 0.031 
 Tnfsf10 41.9 0.002 92.1 0.001 
 Trim21 2.2 0.034 3.1 0.021 
 Trp53 -2.4 0.010 -2.5 0.005 
 Tyk2 -1.5 0.009 -1.1 0.007 
 Vcam1 8.4 0.008 27.7 0.003 
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Table A-3: Expression of IFN and related genes at 36 hours p.i.  Fold change is 
relative to gene expression at time 0. 
GENE ID ADAMES BALLIET 
 Fold Change p-value Fold Change p-value 
 Adar 1.7 0.0 43 1.6 0.009 
 Ciita -1.3 0.022 -1.9 0.010 
 Cxcl10 127.0 0.006 357.5 0.003 
 Cxcl11 14.9 0.022 67.3 0.002 
 Cxcl9 14.0 0.013 34.3 0.004 
 D430028G21Rik -3.0 0.011 -4.3 0.006 
 Eif2ak2 2.3 0.033 1.6 0.031 
 Eif4g2 -3.1 0.016 -5.5 0.008 
 Fas -1.3 0.022 1.2 0.008 
 H2-D1 1.2 0.013 -1.6 0.006 
 Hdac1 -2.1 0.014 -2.6 0.008 
 Ifi203 2.2 0.040 2.0 0.034 
 Ifi204 5.3 0.024 3.2  NS  
 Ifi27 20.6 0.003 18.2 0.006 
 Ifi30 -2.7 0.013 -3.7 0.009 
 Ifi35 2.7 0.009 2.5 0.005 
 Ifi44 768.4 0.001 744.2 0.001 
 Ifi47 12.5 0.003 11.9 0.003 
 Ifih1 3.5 0.009 2.8 0.013 
 Ifit1 97.9 0.011 117.7 0.012 
 Ifit2 205.1 0.010 161.1 0.011 
 Ifit3 242.1 0.001 196.7 0.001 
 Ifitm3 7.9 0.008 5.4 0.006 
 Ifna5 7.6 0.020 15.0 0.002 
 Ifnar1 -2.8 0.012 -5.1 0.005 
 Ifnar2 -2.1 0.019 -3.3 0.010 
 Ifnb1 28.0 0.002 54.5 0.003 
 Ifngr1 -3.2 0.017 -5.8 0.008 
 Ifngr2 -2.0 0.019 -3.5 0.009 
 Igtp 8.5 0.004 10.8 0.003 
 Iigp1 56.0 0.020 115.4 0.016 
 Iigp2 9.7 0.011 9.6 0.008 
 Ikbke -1.8 0.024 -2.3 0.014 
 Il10  -1.6 0.033 1.4 0.022 
 Il10rb -2.6 0.019 -3.4 0.007 
 Il6  1.4  NS 10.5 0.016 
 Il6st -3.5 0.006 -6.3 0.003 
 Irf1 3.2 0.029 3.4 0.018 
 Irf2 -1.7 0.016 -2.3 0.011 
 Irf3 -2.6  NS -3.9 0.031 
 Irf4 -2.3 0.030 -3.0 0.016 
 Irf5 -1.9 0.019 -2.6 0.011 
 Irf7 67.3 0.003 57.3 0.004 
 Irf8 -3.0 0.019 -5.5 0.004 
 Isg20 66.4 0.002 76.2 0.001 
 Jak1 -2.7 0.010 -3.3 0.008 
 Mx1 68.0 0.005 57.6 0.007 
 Mx2 61.9 0.002 61.2 0.002 
 Myc -12.3 0.007 -27.5 0.003  
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Table A-3 (continued): Expression of IFN and related genes at 36 hours p.i.  Fold 
change is relative to gene expression at time 0. 
GENE ID ADAMES BALLIET 
 Fold Change p-value Fold Change p-value 
 Oas1b 9.1 0.010 10.5 0.006 
 Oas2 13.2 0.018 10.6 0.018 
 Pias1 -2.1 0.011 -3.0 0.008 
 Psmb9 1.8 0.010 1.8 0.006 
 Psme1 2.0 0.027 2.1 0.021 
 Rb1 -5.5 0.003 -9.1 0.003 
 Rn18s 4.4 0.050 -7.1 0.039 
 Sfpi1 -2.9 0.010 -3.1 0.009 
 Socs1 5.9 0.006 11.9 0.003 
 Spp1 -4.2 0.005 -7.6 0.003 
 Stat1 4.6 0.005 4.2 0.004 
 Stat2 7.7 0.009 6.4 0.007 
 Tap1 4.1 0.013 4.4 0.007 
 Tgfb1 -2.8 0.020 -4.6 0.011 
 Ticam1 -2.3 0.020 -3.4 0.013 
 Tlr9 6.9 0.038 7.7 0.030 
 Tnfsf10 35.3 0.003 42.3 0.003 
 Trim21 2.7 0.031 3.4 0.021 
 Trp53 -1.5 0.014 -2.0 0.010 
 Vcam1 13.3 0.005 36.1 0.005 
 79
 
Table A-4: Expression of IFN and related genes at 48 hours p.i.  Fold change is 
relative to gene expression at time 0. 
GENE ID ADAMES BALLIET 
 Fold Change p-value Fold Change p-value 
 Adar 2.2 0.014 2.3 0.024 
 Ciita -2.4  NS -1.7 0.022 
 Cxcl10 33.0 0.013 48.7 0.008 
 Cxcl11 2.8  NS 13.1 0.010 
 Cxcl9 4.0  NS 17.0 0.019 
 D430028G21Rik -2.7 0.017 -2.9 0.029
 Eif2ak2 2.2 0.028 1.6  NS 
 Eif4g2 -2.5 0.024 -2.5 0.031 
 Hdac1 -2.2 0.016 -2.4 0.013 
 Ifi203 2.6 0.050 1.2 0.043 
 Ifi204 5.5 0.007 3.2  NS 
 Ifi27 20.6 0.003 27.0 0.005 
 Ifi30 -3.1 0.010 -2.5 0.023 
 Ifi35 2.0 0.015 1.9 0.024 
 Ifi44 593.0 0.001 818.5 0.000 
 Ifi47 8.2 0.005 10.4 0.013 
 Ifih1 3.1 0.013 2.5 0.014 
 Ifit1 79.0 0.012 115.6 0.006 
 Ifit2 154.6 0.011 158.9 0.008 
 Ifit3 158.6 0.001 202.5 0.001 
 Ifitm1 4.6 0.071 4.3 0.046 
 Ifitm3 6.5 0.011 7.1 0.014 
 Ifnar1 -2.3 0.020 -4.6 0.048 
 Ifnar2 -1.7 0.024 -2.1 0.029 
 Ifnb1 15.7 0.005 15.3 0.006 
 Ifngr1 -2.0 0.032 -2.0 0.032 
 Ifngr2 -1.8 0.029 -3.4 0.034 
 Igtp 5.5 0.011 6.7 0.009 
 Iigp1 33.4 0.016 55.8 0.015 
 Iigp2 5.2 0.024 9.3 0.014 
 Ikbke -1.9 0.028 -2.7 0.030 
 Il10rb -2.1 0.017 -2.2 0.020 
 Il1b 12.8 0.013 12.0 0.017 
 Il4ra 1.5 0.017 2.0 0.029 
 Il6 4.7 0.039 1.2  NS 
 Il6st -3.4 0.008 -4.6 0.009 
 Irf1 2.4 0.040 2.8 0.043 
 Irf2 -1.6 0.027 -1.5 0.019 
 Irf4 -1.9 0.044 -1.9 0.027 
 Irf5 -2.0 0.020 -1.8 0.018 
 Irf7 42.7 0.004 55.7 0.004 
 Irf8 -2.2 0.021 -4.0 0.009 
 Isg20 30.4 0.004 61.6 0.003 
 Jak1 -2.2 0.014 -2.1 0.017 
 Mx1 50.5 0.005 53.3 0.005 
 Mx2 44.8 0.003 54.2 0.003 
 Myc -9.6 0.009 -28.1 0.003 
 Myd88 -1.1 0.013 -1.3 0.016 
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Table A-4 (continued): Expression of IFN and related genes at 48 hours p.i.  Fold 
change is relative to gene expression at time 0. 
GENE ID ADAMES BALLIET 
 Fold Change p-value Fold Change p-value 
 Oas1b 6.1 0.010 11.2 0.011 
 Oas2 14.7 0.014 15.3 0.015 
 Pias1 -1.9 0.019 -2.3 0.021 
 Psmb9 1.5 0.015 1.0 0.022
 Psme1 1.7 0.038 1.8 0.031 
 Rb1 -4.1 0.005 -5.1 0.011 
 Rn18s -4.5 0.047 -8.1 0.037 
 Rnasel 1.1 0.023 -1.0 0.018 
 Sfpi1 -2.3 0.012 -3.4 0.017 
 Socs1 3.8 0.017 6.2 0.022 
 Spp1 -4.2 0.006 -5.6 0.010 
 Stat1 3.5 0.007 4.1 0.009 
 Stat2 5.9 0.012 7.0 0.016 
 Tap1 3.5 0.015 5.2 0.012 
 Tgfb1 -2.8 0.021 -2.9 0.019 
 Ticam1 -2.0 0.031 -1.9 0.026 
 Tlr7 1.3 0.015 1.1 0.019 
 Tlr9 4.2  NS 7.1 0.035 
 Tnfsf10 12.1 0.007 11.5 0.010
 Trim21 1.8 0.050 2.6 0.038 
 Trp53 -1.5 0.014 -1.3 0.021 
 Tyk2 -1.5 0.015 -1.8 0.034 
 Vcam1 8.0  NS 12.7  NS
  
 
 
Figure A-1:  Expression of IFN and related genes at 16 hours p.i.  Fold change is relative to gene expression at time 0.  * p < 0.05 
comparing gene expression in cells infected with PTV-A vs. PTV-B. 
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Figure A-2:  Expression of IFN and related genes at 24 hours p.i.  Fold change is relative to gene expression at time 0.  * p < 0.05 
comparing gene expression in cells infected with PTV-A vs. PTV-B. 82 
  
 
 
Figure A-3:  Expression of IFN and related genes at 36 hours p.i.  Fold change is relative to gene expression at time 0.  * p < 0.05 
comparing gene expression in cells infected with PTV-A vs. PTV-B. 83 
  
 
 
Figure A-4:  Expression of IFN and related genes at 48 hours p.i.  Fold change is relative to gene expression at time 0.  * p < 0.05 
comparing gene expression in cells infected with PTV-A vs. PTV-B. 84 
